k141_78_54	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	32.3	421	431	444	1.64e-57	194
k141_113835_4	SARG|gi|639209604|ref|WP_024547784.1|	28.9	235	498	648	1.11e-19	91.3
k141_113835_4	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	27.8	234	498	293	5.72e-16	77.4
k141_113835_4	SARG|gb|AAC75271.1|ARO:3003952|yojI	26.7	240	498	547	5.07e-12	67.0
k141_113835_4	SARG|gb|QNR09092.1|ARO:3007042|msr(G)	23.2	198	498	485	2.72e-08	55.1
k141_113835_4	SARG|QHW12308.1	26.2	195	498	486	8.33e-08	53.5
k141_113835_4	SARG|gb|AAK76137.1|ARO:3000024|patA	23.1	234	498	564	1.21e-07	53.1
k141_113835_4	SARG|gb|WP_104671188.1|ARO:3003948|efrA	22.6	217	498	575	4.89e-07	51.2
k141_113835_4	SARG|DAC81085.1	23.5	196	498	486	5.88e-07	50.8
k141_113835_4	SARG|gb|QHW12375.1|ARO:3005087|msrF	25.6	195	498	486	1.36e-06	49.7
k141_113835_17	SARG|gb|AAC75314.1|ARO:3003578|pmrF	24.9	325	318	322	3.29e-23	96.7
k141_113835_30	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.5	228	231	232	4.58e-36	126
k141_113835_30	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.5	228	231	232	4.58e-36	126
k141_113835_30	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.8	223	231	219	2.00e-34	121
k141_113835_30	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.8	223	231	219	2.81e-34	121
k141_113835_30	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.8	223	231	220	2.89e-34	121
k141_113835_30	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.8	223	231	220	4.07e-34	120
k141_113835_30	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.6	224	231	220	3.17e-33	118
k141_113835_30	SARG|ZP_02848503	34.9	232	231	221	4.99e-32	115
k141_113835_30	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.9	235	231	231	1.26e-31	114
k141_113835_30	CARD|gb|AAD51348.1|ARO:3003066|smeR	35.2	227	231	229	3.34e-31	113
k141_113835_31	CARD|gb|AAD51347.1|ARO:3003067|smeS	27.7	206	342	467	2.24e-18	84.7
k141_113835_31	CARD|gb|BAB38260.1|ARO:3000830|cpxA	29.2	219	342	457	3.15e-17	81.3
k141_113835_31	CARD|gb|CYF42523.1|ARO:3004047|kdpD	25.8	217	342	885	3.96e-15	75.5
k141_113835_32	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	46.3	227	225	255	2.42e-63	196
k141_113835_32	SARG|Q83LR7	44.1	222	225	648	1.04e-52	178
k141_113835_32	SARG|gi|647325472|ref|WP_025760953.1|	44.1	222	225	648	1.04e-52	178
k141_113835_32	SARG|gi|647323678|ref|WP_025760497.1|	44.1	222	225	648	1.04e-52	178
k141_113835_32	SARG|gi|446110305|ref|WP_000188160.1|	43.7	222	225	648	3.89e-52	177
k141_113835_32	SARG|gi|693054987|ref|WP_032223114.1|	43.7	222	225	648	1.45e-51	175
k141_113835_32	SARG|gi|446110301|ref|WP_000188156.1|	43.7	222	225	648	2.01e-51	175
k141_113835_32	SARG|gi|639225329|ref|WP_024561799.1|	42.7	220	225	648	3.88e-51	174
k141_113835_32	SARG|gi|446110272|ref|WP_000188127.1|	43.7	222	225	648	3.88e-51	174
k141_113835_32	SARG|gi|639218559|ref|WP_024556062.1|	42.7	220	225	648	3.88e-51	174
k141_113835_35	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	44.1	222	223	255	6.09e-58	182
k141_113835_35	SARG|gi|565651791|ref|WP_023899061.1|	43.0	223	223	647	9.62e-52	176
k141_113835_35	SARG|gi|742378414|ref|WP_038857601.1|	43.5	223	223	647	9.62e-52	176
k141_113835_35	SARG|gi|657888313|ref|WP_029592374.1|	42.2	223	223	648	1.35e-51	175
k141_113835_35	SARG|gi|754927849|ref|WP_042284850.1|	42.0	224	223	648	1.35e-51	175
k141_113835_35	SARG|gi|495067432|ref|WP_007792257.1|	43.0	223	223	647	1.86e-51	175
k141_113835_35	SARG|gi|763399392|ref|WP_044256358.1|	41.5	224	223	648	1.88e-51	175
k141_113835_35	SARG|gi|696411918|ref|WP_032982657.1|	43.0	223	223	647	2.58e-51	174
k141_113835_35	SARG|gi|494938585|ref|WP_007664615.1|	43.5	223	223	647	2.58e-51	174
k141_113835_35	SARG|gi|1035706844|ref|WP_064548272.1|	42.6	223	223	648	2.61e-51	174
k141_113835_36	megares|MEG_7331|Drugs|Glycopeptide|VanA-type_resistance_protein|VAN_1	65.8	38	857	114	5.71e-10	56.6
k141_113835_36	CARD|gb|AAO82019.1|ARO:3004254|vanV_in_vanB_cl	65.8	38	857	114	5.71e-10	56.6
k141_35983_103	CARD|gb|ADM92605.1|ARO:3000553|adeR	36.5	230	231	247	3.07e-37	129
k141_35983_103	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	35.0	234	231	230	1.71e-35	124
k141_35983_103	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.3	230	231	228	7.01e-34	120
k141_35983_103	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.6	232	231	231	7.55e-34	120
k141_35983_103	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	32.4	244	231	239	2.56e-33	119
k141_35983_103	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	32.1	237	231	232	3.04e-33	119
k141_35983_103	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	32.5	237	231	232	4.27e-33	118
k141_35983_103	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	32.1	237	231	233	4.38e-33	118
k141_35983_103	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.0	226	231	219	8.61e-33	117
k141_35983_103	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.2	237	231	232	2.35e-32	116
k141_35983_105	CARD|gb|ABD30512.1|ARO:3000839|arlS	31.9	251	449	451	3.75e-29	117
k141_35983_105	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.9	240	449	381	4.99e-22	96.3
k141_35983_105	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.9	240	449	381	4.99e-22	96.3
k141_35983_105	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.9	240	449	381	1.02e-20	92.4
k141_35983_105	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.9	240	449	381	1.02e-20	92.4
k141_35983_105	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	27.9	251	449	392	1.52e-20	92.0
k141_35983_105	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	28.0	239	449	364	3.85e-20	90.5
k141_35983_105	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	28.0	239	449	364	3.85e-20	90.5
k141_35983_105	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.1	240	449	381	4.55e-20	90.5
k141_35983_105	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.1	240	449	381	4.55e-20	90.5
k141_35983_106	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.8	227	225	231	5.60e-48	156
k141_35983_106	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	38.1	226	225	232	4.10e-45	149
k141_35983_106	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.4	221	225	219	6.38e-44	145
k141_35983_106	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.4	221	225	220	6.56e-44	145
k141_35983_106	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.4	221	225	220	9.27e-44	145
k141_35983_106	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.1	221	225	228	4.61e-43	144
k141_35983_106	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.9	221	225	219	5.07e-43	143
k141_35983_106	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.1	226	225	231	9.98e-43	143
k141_35983_106	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.1	226	225	231	1.41e-42	142
k141_35983_106	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.6	226	225	231	2.81e-42	142
k141_35983_109	megares|MEG_7070|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|TETD_1	37.4	99	294	138	5.05e-16	72.4
k141_65957_5	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	31.2	218	232	293	2.02e-35	126
k141_65957_5	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	31.3	227	232	307	3.99e-27	104
k141_65957_5	SARG|gi|445996719|ref|WP_000074574.1|	28.3	230	232	309	2.22e-24	97.4
k141_65957_5	SARG|gi|446026113|ref|WP_000103968.1|	27.8	230	232	306	4.09e-24	96.7
k141_65957_5	SARG|gi|895736250|emb|COF64653.1|	28.3	230	232	309	5.95e-24	96.3
k141_65957_5	SARG|gi|446110087|ref|WP_000187942.1|	28.3	230	232	309	5.95e-24	96.3
k141_65957_5	SARG|gi|445996710|ref|WP_000074565.1|	28.3	230	232	309	5.95e-24	96.3
k141_65957_5	SARG|gi|445996722|ref|WP_000074577.1|	28.7	230	232	309	5.95e-24	96.3
k141_65957_5	SARG|gi|895808656|emb|COR83787.1|	28.3	230	232	309	5.95e-24	96.3
k141_65957_5	SARG|gi|445996714|ref|WP_000074569.1|	28.3	230	232	309	8.27e-24	95.9
k141_42086_1	SARG|gi|446048013|ref|WP_000125868.1|	35.1	74	79	648	6.53e-10	52.4
k141_42086_1	SARG|P42332	30.6	72	79	306	3.95e-09	50.1
k141_42086_1	SARG|AAD21213	30.6	72	79	306	3.95e-09	50.1
k141_42086_1	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	30.6	72	79	306	3.95e-09	50.1
k141_42086_1	SARG|gi|510143239|gb|AGN36970.1|	30.6	72	79	313	3.98e-09	50.1
k141_42086_1	SARG|ABB80128	30.6	72	79	306	7.41e-09	49.3
k141_42086_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.0	54	79	664	1.09e-08	48.9
k141_42086_1	SARG|YP_001373621	30.8	65	79	318	1.40e-08	48.5
k141_42086_9	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	26.8	261	446	355	1.02e-20	92.0
k141_42086_9	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	26.8	261	446	355	1.02e-20	92.0
k141_42086_9	SARG|ACM47285	26.8	261	446	363	1.12e-20	92.0
k141_42086_9	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	25.4	283	446	356	2.56e-20	90.9
k141_42086_9	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	25.4	283	446	356	1.15e-19	89.0
k141_42086_9	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	26.4	261	446	355	2.08e-19	88.2
k141_42086_9	SARG|BAE96115	26.4	261	446	355	2.08e-19	88.2
k141_42086_9	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	25.1	259	446	356	1.27e-18	85.9
k141_42086_9	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	24.7	259	446	346	2.27e-17	82.0
k141_42086_9	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	26.2	202	446	209	6.03e-11	60.8
k141_42086_10	NCBI|WP_011860980.1|1|1|blaAHM-1|blaAHM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3-like_metallo-beta-lactamase_AHM-1|AMR|beta-lactam	31.8	299	329	304	5.24e-39	139
k141_54112_2	megares|MEG_3786|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	25.8	322	584	585	1.72e-22	100
k141_54112_2	NCBI|WP_000952923.1|1|1|mecR1|mecR1|regulation|2|METHICILLIN|beta-lactam|beta-lactam_sensor/signal_transducer_MecR1|AMR|beta-lactam	25.8	322	584	585	1.72e-22	100
k141_54112_16	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	28.2	682	669	641	2.83e-56	201
k141_54112_17	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	49.4	247	250	255	6.84e-80	239
k141_54112_17	SARG|gb|AAV85982.1|ARO:3000535|macB	39.8	226	250	644	1.11e-46	163
k141_54112_17	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.2	216	250	664	1.91e-18	83.2
k141_54112_32	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	24.4	164	252	231	2.48e-06	46.2
k141_54112_32	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	24.4	164	252	231	4.51e-06	45.4
k141_54112_32	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	24.4	164	252	231	8.19e-06	44.7
k141_54112_43	SARG|gi|1004359922|gb|AMP42228.1|	26.7	453	606	639	5.93e-30	124
k141_54112_43	SARG|gb|AMP42147.1|ARO:3004442|tet(W/N/W)	26.7	454	606	639	1.07e-28	120
k141_54112_43	SARG|AAY62597	26.4	454	606	639	6.03e-28	117
k141_54112_43	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.9	454	606	629	7.74e-28	117
k141_54112_43	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.9	454	606	629	7.74e-28	117
k141_54112_43	ResF|tet(O/W)_3_AM889120_1	26.9	454	606	639	8.04e-28	117
k141_54112_43	ResF|tet(O/W)_4_AM889121_1	26.9	454	606	639	8.04e-28	117
k141_54112_43	SARG|gi|254967129|gb|ACT97610.1|	26.4	454	606	639	1.07e-27	117
k141_54112_43	SARG|AJ222769.gene.p01	26.4	454	606	639	1.07e-27	117
k141_54112_43	SARG|gi|1028100281|ref|WP_063856416.1|	26.4	454	606	639	1.07e-27	117
k141_54112_76	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.9	116	121	228	1.23e-16	71.6
k141_54112_76	CARD|gb|BAB36671.1|ARO:3000832|evgA	29.2	113	121	204	1.36e-13	63.2
k141_54112_76	CARD|gb|AAD51348.1|ARO:3003066|smeR	28.2	117	121	229	7.00e-13	61.6
k141_54112_76	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	32.0	103	121	225	3.47e-12	59.7
k141_54112_76	CARD|gb|AAC73788.1|ARO:3003841|kdpE	32.0	103	121	225	3.47e-12	59.7
k141_84054_1	NCBI|WP_063843212.1|1|1|catA5|catA5|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_A-5_phenicol_O-acetyltransferase|AMR|phenicol	33.3	72	77	220	5.10e-14	62.8
k141_84054_1	SARG|M90091.1.gene2.p01	33.3	69	77	215	7.09e-12	57.0
k141_84054_1	SARG|YP_001429537	33.3	69	77	215	7.09e-12	57.0
k141_84054_1	SARG|M58515.1.gene2.p01	33.3	69	77	219	7.38e-12	57.0
k141_84054_2	CARD|gb|CAL34518.1|ARO:3000526|cmeR	44.9	49	218	210	2.83e-06	45.4
k141_84054_3	NCBI|WP_070509550.1|1|1|mef(H)|mef(H)|efflux|2|ERYTHROMYCIN|MACROLIDE|macrolide_efflux_MFS_transporter_Mef(H)|AMR|macrolide	35.5	408	418	412	2.52e-76	242
k141_84054_3	SARG|gb|QQM99829.1|ARO:3007047|mefH	39.2	74	418	109	2.91e-12	62.0
k141_84129_30	SARG|gb|WP_009089555.1|ARO:3005669|GOB-20	30.5	131	211	290	1.63e-12	63.9
k141_84129_30	SARG|gb|AAT68577.1|ARO:3004802|GOB-10	30.5	131	211	290	1.63e-12	63.9
k141_84129_30	SARG|gb|WP_058879139.1|ARO:3005687|GOB-38	30.5	131	211	290	1.63e-12	63.9
k141_84129_30	SARG|gb|AAQ54756.1|ARO:3004815|GOB-8	30.5	131	211	290	1.63e-12	63.9
k141_84129_30	SARG|gb|AAT68576.1|ARO:3004816|GOB-9	30.5	131	211	290	1.63e-12	63.9
k141_84129_30	SARG|gb|WP_011094382.1|ARO:3006903|CAR-1	37.1	97	211	342	1.81e-11	61.2
k141_78143_3	SARG|gb|CAE00499.1|ARO:3003835|cdeA	38.5	441	444	441	7.98e-106	320
k141_36297_6	SARG|YP_001373621	35.2	227	339	318	2.12e-32	122
k141_36297_6	SARG|P42332	32.8	253	339	306	2.32e-32	121
k141_36297_6	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	32.8	253	339	306	2.32e-32	121
k141_36297_6	SARG|gi|510143239|gb|AGN36970.1|	32.8	253	339	313	2.67e-32	121
k141_36297_6	SARG|gi|542061059|gb|ERI11611.1|	33.3	261	339	316	2.84e-32	121
k141_36297_6	SARG|ABB80128	32.8	253	339	306	4.49e-32	120
k141_36297_6	SARG|AAD21213	32.4	253	339	306	1.68e-31	119
k141_138182_81	SARG|gi|542061059|gb|ERI11611.1|	33.3	306	352	316	1.46e-51	172
k141_138182_81	SARG|gi|447195835|ref|WP_001273091.1|	35.1	308	352	306	6.70e-50	168
k141_138182_81	SARG|gi|447195836|ref|WP_001273092.1|	34.7	308	352	306	1.86e-49	167
k141_138182_81	SARG|gi|445996708|ref|WP_000074563.1|	33.2	307	352	309	2.82e-49	166
k141_138182_81	SARG|YP_001373621	34.2	307	352	318	3.56e-49	166
k141_138182_81	SARG|gi|507055561|ref|WP_016126482.1|	33.3	309	352	309	3.97e-49	166
k141_138182_81	SARG|gi|487936534|ref|WP_002010000.1|	33.7	309	352	309	3.97e-49	166
k141_138182_81	SARG|gi|488068784|ref|WP_002140181.1|	33.6	307	352	309	3.97e-49	166
k141_138182_81	SARG|gi|445996709|ref|WP_000074564.1|	33.9	307	352	309	5.57e-49	166
k141_138182_81	SARG|gi|445996710|ref|WP_000074565.1|	33.9	307	352	309	5.57e-49	166
k141_6613_10	SARG|gi|445996719|ref|WP_000074574.1|	33.2	214	283	309	7.48e-28	108
k141_6613_10	SARG|gi|446026113|ref|WP_000103968.1|	33.2	214	283	306	2.65e-27	106
k141_6613_10	SARG|gi|507035724|ref|WP_016107411.1|	32.7	202	283	309	7.51e-27	105
k141_6613_10	SARG|gi|445996698|ref|WP_000074553.1|	32.7	202	283	309	7.51e-27	105
k141_6613_10	SARG|gi|500448961|gb|EOP61695.1|	32.5	200	283	306	9.91e-27	105
k141_6613_10	SARG|gi|445996709|ref|WP_000074564.1|	33.5	200	283	309	1.04e-26	105
k141_6613_10	SARG|gi|445996697|ref|WP_000074552.1|	32.7	202	283	309	1.04e-26	105
k141_6613_10	SARG|gi|445996723|ref|WP_000074578.1|	32.7	214	283	309	1.04e-26	105
k141_6613_10	SARG|gi|445996696|ref|WP_000074551.1|	32.7	202	283	309	1.04e-26	105
k141_6613_10	SARG|gi|445996722|ref|WP_000074577.1|	32.2	214	283	309	1.45e-26	104
k141_6613_11	SARG|gi|502669352|ref|WP_012905216.1|	32.9	225	288	648	1.80e-23	99.0
k141_6613_11	SARG|gi|803568669|ref|WP_046077412.1|	31.9	207	288	648	1.37e-20	90.5
k141_6613_11	SARG|gi|446110352|ref|WP_000188207.1|	31.9	207	288	648	1.37e-20	90.5
k141_6613_11	SARG|YP_002382193	31.9	207	288	648	1.37e-20	90.5
k141_6613_11	SARG|gi|803575554|ref|WP_046081557.1|	31.9	207	288	648	1.37e-20	90.5
k141_6613_11	SARG|gi|446110351|ref|WP_000188206.1|	31.9	207	288	648	1.37e-20	90.5
k141_6613_11	SARG|gb|AAK76137.1|ARO:3000024|patA	26.5	211	288	564	3.45e-19	86.3
k141_6613_11	SARG|gi|953808775|ref|WP_058042812.1|	28.6	245	288	608	1.62e-18	84.3
k141_6613_11	SARG|gi|736472622|ref|WP_034494292.1|	29.1	227	288	648	3.04e-18	83.6
k141_6613_11	SARG|gi|1035706844|ref|WP_064548272.1|	28.6	227	288	648	1.35e-17	81.6
k141_6613_15	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	34.7	259	259	255	4.95e-43	145
k141_6613_15	SARG|gi|746243059|ref|WP_039291473.1|	35.0	234	259	648	2.79e-39	143
k141_6613_15	SARG|gi|746253210|ref|WP_039301529.1|	34.2	234	259	648	3.54e-38	140
k141_6613_15	SARG|gi|495736522|ref|WP_008461101.1|	34.2	234	259	648	6.66e-38	139
k141_6613_15	SARG|gi|1001720867|ref|WP_061274204.1|	33.8	234	259	648	1.25e-37	138
k141_6613_15	SARG|gi|657888313|ref|WP_029592374.1|	34.9	238	259	648	3.24e-37	137
k141_6613_15	SARG|gi|639225329|ref|WP_024561799.1|	34.9	238	259	648	4.44e-37	137
k141_6613_15	SARG|gi|639218559|ref|WP_024556062.1|	34.9	238	259	648	4.44e-37	137
k141_6613_15	SARG|gi|639216333|ref|WP_024554080.1|	34.9	238	259	648	4.44e-37	137
k141_6613_15	SARG|gi|751930065|ref|WP_041144773.1|	35.6	239	259	648	6.09e-37	136
k141_6613_19	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	41.2	226	237	255	2.39e-61	192
k141_6613_19	SARG|gi|896325272|ref|WP_049294291.1|	42.1	240	237	648	1.56e-54	184
k141_6613_19	SARG|gi|983405167|ref|WP_060572706.1|	42.4	236	237	646	2.12e-54	183
k141_6613_19	SARG|gb|AAV85982.1|ARO:3000535|macB	40.5	227	237	644	2.87e-54	183
k141_6613_19	SARG|gi|657888313|ref|WP_029592374.1|	42.8	222	237	648	3.03e-54	183
k141_6613_19	SARG|gi|639225329|ref|WP_024561799.1|	42.8	222	237	648	3.03e-54	183
k141_6613_19	SARG|gi|639218559|ref|WP_024556062.1|	42.8	222	237	648	3.03e-54	183
k141_6613_19	SARG|gi|639216333|ref|WP_024554080.1|	42.8	222	237	648	4.21e-54	182
k141_6613_19	SARG|gi|782756348|ref|WP_045630015.1|	42.4	236	237	646	7.94e-54	182
k141_6613_19	SARG|gi|754493745|ref|WP_041910640.1|	41.9	236	237	646	1.10e-53	181
k141_6613_22	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.2	220	224	219	7.77e-42	140
k141_6613_22	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.2	220	224	219	1.10e-41	140
k141_6613_22	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.2	220	224	220	1.13e-41	140
k141_6613_22	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.2	220	224	220	1.59e-41	139
k141_6613_22	SARG|ZP_02848503	37.5	224	224	221	5.01e-37	128
k141_6613_22	CARD|gb|ATC67679.1|ARO:3000838|arlR	33.9	221	224	219	8.18e-35	122
k141_6613_22	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	32.8	232	224	239	9.63e-35	122
k141_6613_22	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	31.7	227	224	231	1.22e-33	119
k141_6613_22	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	31.3	227	224	231	3.39e-33	118
k141_6613_22	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.9	219	224	228	9.59e-32	114
k141_6613_27	SARG|ACF08831	37.3	134	396	639	3.40e-16	79.3
k141_6613_27	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	36.8	133	396	639	1.91e-15	77.0
k141_6613_28	SARG|NP_348076	27.7	687	706	652	1.32e-75	255
k141_6613_28	SARG|L42544.gene.p01	29.0	672	706	651	2.49e-74	251
k141_6613_28	SARG|AAV80410	28.3	668	706	651	4.80e-74	251
k141_6613_28	SARG|YP_002850805	26.8	694	706	652	2.50e-72	246
k141_6613_28	SARG|ZP_02952732	26.4	692	706	652	9.14e-71	242
k141_6613_28	SARG|ZP_02632674	26.4	692	706	660	1.07e-70	242
k141_6613_28	SARG|L20800.gene.p01	26.4	692	706	652	3.37e-70	240
k141_6613_28	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.5	671	706	639	8.68e-66	228
k141_6613_28	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.9	670	706	629	9.59e-65	225
k141_6613_28	ResF|tet(O/W)_3_AM889120_1	27.9	670	706	639	1.16e-64	225
k141_6613_32	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	51.8	1248	1291	1162	0.0	1178
k141_6613_32	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	50.5	1260	1291	1186	0.0	1142
k141_6613_32	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	50.5	1260	1291	1186	0.0	1142
k141_6613_48	CARD|gb|AAC16242.1|ARO:3005069|rsmA	45.0	60	72	61	1.22e-15	63.2
k141_36444_8	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	27.9	226	438	307	1.26e-18	85.1
k141_36444_8	SARG|gi|1008988570|ref|WP_061884457.1|	31.1	164	438	492	2.41e-10	61.2
k141_36444_8	SARG|gi|765018624|ref|WP_044584737.1|	31.1	164	438	492	3.20e-10	60.8
k141_36444_8	SARG|gi|445983935|ref|WP_000061790.1|	31.1	164	438	492	3.20e-10	60.8
k141_36444_8	SARG|gi|445983943|ref|WP_000061798.1|	31.1	164	438	492	3.20e-10	60.8
k141_36444_8	SARG|gi|1005558399|ref|WP_061655514.1|	31.1	164	438	492	3.20e-10	60.8
k141_36444_8	SARG|gi|445983944|ref|WP_000061799.1|	31.1	164	438	492	3.20e-10	60.8
k141_36444_8	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.3	186	438	655	5.10e-10	60.5
k141_36444_8	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.3	186	438	655	5.10e-10	60.5
k141_36444_8	SARG|gi|1031496106|ref|WP_064100483.1|	27.8	176	438	492	1.31e-09	58.9
k141_36444_23	SARG|gb|AAC75314.1|ARO:3003578|pmrF	29.9	308	312	322	2.19e-42	147
k141_36444_41	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	27.2	404	582	579	9.44e-36	140
k141_36444_41	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	36.8	220	582	574	3.03e-35	139
k141_36444_41	SARG|gb|AAK76136.1|ARO:3000025|patB	26.7	479	582	588	2.08e-34	136
k141_36444_41	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	26.8	403	582	579	2.88e-33	133
k141_36444_41	SARG|gb|CDO61516.1|ARO:3003949|efrB	34.0	203	582	362	5.96e-32	125
k141_36444_41	SARG|gb|AYV52072.1|ARO:3002882|lmrD	32.7	223	582	664	1.70e-30	125
k141_36444_41	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	34.1	220	582	578	4.78e-30	123
k141_36444_41	SARG|gb|AAK76137.1|ARO:3000024|patA	32.1	243	582	564	2.76e-27	115
k141_36444_41	SARG|gi|921979807|ref|WP_053271336.1|	30.0	230	582	648	2.44e-15	78.2
k141_36444_41	SARG|U82085.gene.p01	23.9	218	582	552	2.89e-08	55.5
k141_36444_54	SARG|gb|AAC75314.1|ARO:3003578|pmrF	30.8	315	330	322	7.11e-31	117
k141_36444_75	SARG|gb|AAC75089.1|ARO:3003577|ugd	59.0	410	421	388	1.25e-168	477
k141_84358_23	SARG|gi|1035706844|ref|WP_064548272.1|	33.8	77	951	648	2.48e-07	53.5
k141_114348_5	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	25.0	228	470	359	3.08e-16	79.0
k141_114348_5	CARD|gb|ADM92606.1|ARO:3000549|adeS	26.1	226	470	361	1.40e-14	73.9
k141_114348_5	CARD|gb|AAD51347.1|ARO:3003067|smeS	27.8	212	470	467	6.99e-13	69.3
k141_120537_40	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	31.6	212	288	346	2.75e-17	79.7
k141_120537_58	NCBI|WP_000369214.1|1|1|mecI_of_mecA|mecI_of_mecA||2|METHICILLIN|beta-lactam|mecA-type_methicillin_resistance_repressor_MecI|AMR|beta-lactam	30.3	119	127	123	2.03e-13	61.2
k141_120537_58	NCBI|WP_000369216.1|1|1|mecI_of_mecA|mecI_of_mecA||2|METHICILLIN|beta-lactam|mecA-type_methicillin_resistance_repressor_MecI|AMR|beta-lactam	30.3	119	127	123	2.03e-13	61.2
k141_120537_59	NCBI|WP_012705551.1|1|1|blaR1_gen|blaR1_gen|regulation|2|beta-lactam|beta-lactam|BlaR1_family_beta-lactam_sensor/signal_transducer|AMR|beta-lactam	22.2	383	815	593	1.39e-19	92.4
k141_120537_61	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	29.5	193	236	494	6.28e-17	78.2
k141_120537_61	SARG|gi|445983919|ref|WP_000061774.1|	29.3	191	236	492	8.48e-17	77.8
k141_120537_61	SARG|gi|445983951|ref|WP_000061806.1|	28.9	190	236	492	8.48e-17	77.8
k141_120537_61	SARG|gi|822524709|ref|WP_046954623.1|	28.8	191	236	492	8.48e-17	77.8
k141_120537_61	SARG|gi|516130021|ref|WP_017560601.1|	28.8	191	236	492	1.56e-16	77.0
k141_120537_61	SARG|gb|APB03219.1|ARO:3003986|TaeA	26.4	258	236	648	2.38e-16	76.6
k141_120537_61	SARG|gi|983301550|ref|WP_060487860.1|	28.3	191	236	492	3.87e-16	75.9
k141_120537_61	SARG|gi|817727729|ref|WP_046680744.1|	30.2	192	236	492	3.87e-16	75.9
k141_120537_61	SARG|gi|926250866|ref|WP_053589133.1|	27.9	190	236	492	5.24e-16	75.5
k141_120537_61	SARG|gi|1005577494|ref|WP_061669299.1|	27.9	190	236	492	9.60e-16	74.7
k141_120537_74	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	27.8	115	511	228	6.76e-08	52.4
k141_120537_74	CARD|gb|ADM92605.1|ARO:3000553|adeR	31.4	86	511	247	6.36e-07	49.7
k141_120537_74	CARD|gb|ATC67679.1|ARO:3000838|arlR	30.0	100	511	219	5.21e-06	46.6
k141_42815_5	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	54.7	159	160	159	4.86e-57	174
k141_1085_4	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	23.9	368	463	443	2.05e-14	73.9
k141_1085_15	SARG|gi|500465078|gb|EOP76697.1|	27.9	229	499	306	2.05e-16	79.0
k141_1085_15	SARG|gi|500448961|gb|EOP61695.1|	27.9	229	499	306	2.75e-16	78.6
k141_1085_15	SARG|gi|542061059|gb|ERI11611.1|	27.5	236	499	316	1.36e-15	76.6
k141_1085_15	SARG|gi|447195835|ref|WP_001273091.1|	28.8	226	499	306	2.20e-15	75.9
k141_1085_15	SARG|gi|447195836|ref|WP_001273092.1|	28.8	226	499	306	2.20e-15	75.9
k141_1085_15	SARG|ZP_04081918	29.2	226	499	306	2.96e-15	75.5
k141_1085_15	SARG|gi|507055561|ref|WP_016126482.1|	29.1	227	499	309	4.11e-15	75.1
k141_1085_15	SARG|gi|445996719|ref|WP_000074574.1|	28.6	227	499	309	5.53e-15	74.7
k141_1085_15	SARG|gi|507023808|ref|WP_016095885.1|	29.1	227	499	309	9.98e-15	73.9
k141_1085_15	SARG|gi|445996710|ref|WP_000074565.1|	28.6	227	499	309	9.98e-15	73.9
k141_1085_30	SARG|gi|500465078|gb|EOP76697.1|	27.8	237	510	306	4.13e-15	75.1
k141_1085_30	SARG|gi|500448961|gb|EOP61695.1|	27.8	237	510	306	5.56e-15	74.7
k141_1085_30	SARG|YP_001373621	27.5	240	510	318	8.47e-15	74.3
k141_1085_30	SARG|gi|447195835|ref|WP_001273091.1|	27.5	222	510	306	1.00e-14	73.9
k141_1085_30	SARG|gi|447195836|ref|WP_001273092.1|	27.5	222	510	306	1.00e-14	73.9
k141_1085_30	SARG|P42332	28.0	225	510	306	1.35e-14	73.6
k141_1085_30	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	28.0	225	510	306	1.35e-14	73.6
k141_1085_30	SARG|gi|510143239|gb|AGN36970.1|	28.0	225	510	313	1.45e-14	73.6
k141_1085_30	SARG|ABB80128	28.0	225	510	306	1.81e-14	73.2
k141_1085_30	SARG|ZP_04081918	27.4	215	510	306	1.81e-14	73.2
k141_1085_35	SARG|gi|860594225|ref|WP_048475168.1|	31.6	570	587	620	6.88e-89	286
k141_1085_35	SARG|gi|926376632|ref|WP_053705806.1|	31.9	573	587	620	5.21e-88	284
k141_1085_35	SARG|gi|917166849|ref|WP_051773561.1|	32.3	573	587	620	7.30e-88	283
k141_1085_35	SARG|gi|496018010|ref|WP_008742581.1|	31.6	572	587	623	7.84e-88	283
k141_1085_35	SARG|gi|799286378|ref|WP_045936958.1|	31.9	573	587	620	1.02e-87	283
k141_1085_35	SARG|gi|926294973|ref|WP_053631154.1|	31.9	573	587	620	1.02e-87	283
k141_1085_35	SARG|gi|926356413|ref|WP_053687351.1|	31.9	573	587	620	1.43e-87	283
k141_1085_35	SARG|gi|926345639|ref|WP_053677539.1|	31.9	573	587	620	1.43e-87	283
k141_1085_35	SARG|gi|917155568|ref|WP_051762280.1|	32.1	573	587	620	2.01e-87	282
k141_1085_35	SARG|gi|648667297|ref|WP_026359044.1|	32.1	567	587	605	2.74e-87	281
k141_48792_12	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	28.1	235	249	574	9.60e-19	84.0
k141_48792_12	SARG|gi|1033064422|ref|WP_064375412.1|	30.1	226	249	648	1.85e-18	83.2
k141_48792_12	SARG|gi|1022688710|ref|WP_063443532.1|	30.1	226	249	648	6.20e-18	81.6
k141_48792_12	SARG|gi|823326845|ref|WP_047080664.1|	29.6	226	249	648	8.39e-18	81.3
k141_48792_12	SARG|gi|695793471|ref|WP_032707680.1|	29.6	226	249	648	1.54e-17	80.5
k141_48792_12	SARG|gi|823291602|ref|WP_047047573.1|	29.6	226	249	648	1.54e-17	80.5
k141_48792_12	SARG|gi|823302270|ref|WP_047057473.1|	29.6	226	249	648	1.54e-17	80.5
k141_48792_12	SARG|gi|976146774|ref|WP_059305359.1|	29.6	226	249	648	1.54e-17	80.5
k141_48792_12	SARG|gi|1022664304|ref|WP_063420886.1|	29.6	226	249	648	1.54e-17	80.5
k141_48792_12	SARG|gi|823309640|ref|WP_047064288.1|	29.6	226	249	648	1.54e-17	80.5
k141_6990_16	SARG|M93113.gene.p01	27.1	210	233	219	1.28e-22	90.9
k141_6990_16	SARG|gi|505206451|ref|WP_015393553.1|	27.1	210	233	219	1.28e-22	90.9
k141_6990_16	SARG|gb|ATL63235.1|ARO:3004357|catV	29.4	211	233	219	1.78e-22	90.5
k141_6990_16	SARG|M55620.gene.p01	28.1	221	233	219	1.90e-20	85.1
k141_6990_16	NCBI|WP_063843221.1|1|1|catA16|catA16|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_A-16_phenicol_O-acetyltransferase_CatQ|AMR|phenicol	26.7	221	233	219	5.14e-20	84.0
k141_6990_16	SARG|S48276.1.gene1.p01	26.7	210	233	216	1.81e-15	71.6
k141_6990_17	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	23.6	254	510	357	1.18e-08	55.8
k141_6990_17	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	23.6	254	510	357	1.18e-08	55.8
k141_6990_18	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.9	236	222	232	1.82e-39	134
k141_6990_18	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.9	236	222	232	1.82e-39	134
k141_6990_18	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.0	230	222	231	6.75e-36	125
k141_6990_18	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.0	230	222	231	6.75e-36	125
k141_6990_18	CARD|gb|ATC67679.1|ARO:3000838|arlR	34.9	218	222	219	9.83e-36	124
k141_6990_18	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	32.3	235	222	239	1.64e-35	124
k141_6990_18	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	31.4	229	222	229	1.79e-35	124
k141_6990_18	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.6	226	222	232	2.73e-35	124
k141_6990_18	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.7	230	222	231	3.74e-35	123
k141_6990_18	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.7	230	222	231	7.43e-35	122
k141_108752_11	SARG|gi|542061059|gb|ERI11611.1|	36.6	257	294	316	1.86e-40	142
k141_108752_11	SARG|gi|445996719|ref|WP_000074574.1|	36.9	260	294	309	3.32e-39	138
k141_108752_11	SARG|gi|445996729|ref|WP_000074584.1|	36.2	260	294	309	4.94e-38	135
k141_108752_11	SARG|gi|507044560|ref|WP_016115614.1|	35.8	260	294	306	6.47e-38	135
k141_108752_11	SARG|gi|1043490477|ref|WP_065382463.1|	36.5	260	294	309	9.70e-38	134
k141_108752_11	SARG|gi|445996726|ref|WP_000074581.1|	36.5	260	294	309	9.70e-38	134
k141_108752_11	SARG|gi|884875933|emb|CKG93789.1|	36.2	260	294	309	9.70e-38	134
k141_108752_11	SARG|gi|445996723|ref|WP_000074578.1|	36.5	260	294	309	9.70e-38	134
k141_108752_11	SARG|gi|507054395|ref|WP_016125339.1|	36.5	260	294	309	9.70e-38	134
k141_108752_11	SARG|gi|507035724|ref|WP_016107411.1|	35.8	257	294	309	1.36e-37	134
k141_108752_18	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.9	826	917	1024	4.85e-68	244
k141_108752_18	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.9	826	917	1024	4.85e-68	244
k141_108752_18	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.9	826	917	1024	1.63e-67	243
k141_108752_18	SARG|gb|CAA53189|ARO:3000521|mupA	24.9	826	917	1024	1.63e-67	243
k141_108752_40	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.6	226	229	231	1.65e-35	124
k141_108752_40	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.1	226	229	231	6.50e-35	123
k141_108752_40	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.6	226	229	231	6.50e-35	123
k141_108752_40	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	33.2	226	229	231	3.60e-34	121
k141_108752_40	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.2	226	229	231	3.60e-34	121
k141_108752_40	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.4	218	229	228	2.59e-33	119
k141_108752_40	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	30.6	229	229	232	8.67e-32	115
k141_108752_40	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	30.6	229	229	232	8.67e-32	115
k141_108752_40	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	34.2	222	229	225	1.03e-31	114
k141_108752_40	CARD|gb|AAC73788.1|ARO:3003841|kdpE	34.2	222	229	225	1.03e-31	114
k141_108752_42	SARG|Q83LR7	43.2	222	228	648	1.09e-57	192
k141_108752_42	SARG|gi|647325472|ref|WP_025760953.1|	43.2	222	228	648	1.09e-57	192
k141_108752_42	SARG|gi|647323678|ref|WP_025760497.1|	43.2	222	228	648	1.09e-57	192
k141_108752_42	SARG|gi|491270241|ref|WP_005128370.1|	42.6	223	228	648	2.96e-57	191
k141_108752_42	SARG|gi|851902043|ref|WP_048212057.1|	42.6	223	228	648	2.96e-57	191
k141_108752_42	SARG|gi|992380339|ref|WP_061067665.1|	42.6	223	228	648	2.96e-57	191
k141_108752_42	SARG|gi|446110305|ref|WP_000188160.1|	42.8	222	228	648	4.12e-57	190
k141_108752_42	SARG|gi|895981299|ref|WP_049056431.1|	43.8	224	228	648	5.74e-57	190
k141_108752_42	SARG|gi|823281237|ref|WP_047037467.1|	43.8	224	228	648	5.74e-57	190
k141_108752_42	SARG|gi|895967513|ref|WP_049046752.1|	43.8	224	228	648	5.74e-57	190
k141_108752_54	SARG|L42544.gene.p01	30.6	643	921	651	5.61e-91	301
k141_108752_54	SARG|AAV80410	30.6	643	921	651	1.08e-90	300
k141_108752_54	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	32.3	613	921	641	4.37e-88	293
k141_108752_54	SARG|AAZ79478	32.3	613	921	657	6.40e-88	293
k141_108752_54	SARG|NP_348076	29.8	647	921	652	2.93e-87	291
k141_108752_54	SARG|AJ514254.gene.p01	31.8	623	921	640	3.02e-86	288
k141_108752_54	SARG|YP_002850805	30.6	644	921	652	4.01e-86	288
k141_108752_54	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	31.8	613	921	654	4.20e-86	288
k141_108752_54	SARG|Q08425	31.6	613	921	641	5.95e-86	287
k141_108752_54	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	31.8	613	921	670	6.09e-86	288
k141_12840_1	CARD|gb|AFK13828.1|ARO:3000823|ramA	28.3	99	305	124	6.27e-12	60.8
k141_12840_13	SARG|gi|1001720867|ref|WP_061274204.1|	46.6	219	230	648	1.20e-56	189
k141_12840_13	SARG|gi|851928815|ref|WP_048221086.1|	45.2	221	230	648	1.20e-56	189
k141_12840_13	SARG|gi|780033092|ref|WP_045444768.1|	45.2	221	230	648	1.20e-56	189
k141_12840_13	SARG|gi|746253210|ref|WP_039301529.1|	46.6	219	230	648	1.66e-56	189
k141_12840_13	SARG|gi|495736522|ref|WP_008461101.1|	46.6	219	230	648	3.23e-56	188
k141_12840_13	SARG|gi|746243059|ref|WP_039291473.1|	46.6	219	230	648	8.72e-56	187
k141_12840_13	SARG|gi|657888313|ref|WP_029592374.1|	45.2	219	230	648	1.69e-55	186
k141_12840_13	SARG|gi|1035706844|ref|WP_064548272.1|	44.1	227	230	648	1.69e-55	186
k141_12840_13	SARG|gi|736472622|ref|WP_034494292.1|	43.6	227	230	648	4.56e-55	185
k141_12840_13	SARG|gi|639225329|ref|WP_024561799.1|	44.7	219	230	648	1.23e-54	184
k141_12840_14	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	25.1	219	330	370	4.70e-13	68.2
k141_12840_14	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	23.3	219	330	365	4.85e-12	65.1
k141_12840_15	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.4	222	227	228	2.38e-52	167
k141_12840_15	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.0	227	227	230	1.31e-46	153
k141_12840_15	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.4	226	227	232	1.38e-46	153
k141_12840_15	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.4	226	227	232	1.38e-46	153
k141_12840_15	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.4	228	227	229	1.79e-46	152
k141_12840_15	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.0	226	227	231	5.36e-46	151
k141_12840_15	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.5	226	227	231	1.07e-45	150
k141_12840_15	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.8	226	227	231	3.01e-45	149
k141_12840_15	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.0	226	227	231	3.01e-45	149
k141_12840_15	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	36.6	232	227	233	3.19e-45	149
k141_12840_22	SARG|gi|486458841|gb|EOE03251.1|	35.4	79	311	237	3.64e-07	49.3
k141_12840_23	megares|MEG_1289|Drugs|beta-lactam|Penicillin_binding_protein_regulator|BLAI_1	37.3	118	132	126	2.23e-26	94.7
k141_12840_24	CARD|gb|ABU39979.1|ARO:3000217|blaR1	38.2	574	603	588	1.17e-118	363
k141_12840_24	NCBI|WP_012705551.1|1|1|blaR1_gen|blaR1_gen|regulation|2|beta-lactam|beta-lactam|BlaR1_family_beta-lactam_sensor/signal_transducer|AMR|beta-lactam	33.9	587	603	593	1.90e-99	313
k141_12840_24	megares|MEG_3786|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	30.6	595	603	585	5.01e-87	281
k141_12840_24	NCBI|WP_000952923.1|1|1|mecR1|mecR1|regulation|2|METHICILLIN|beta-lactam|beta-lactam_sensor/signal_transducer_MecR1|AMR|beta-lactam	30.6	595	603	585	5.01e-87	281
k141_12840_24	NCBI|WP_001096386.1|1|1|blaR1-2|blaR1-2|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	28.7	589	603	585	1.94e-69	234
k141_12840_24	NCBI|WP_001096392.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	28.0	589	603	585	5.32e-68	230
k141_12840_24	NCBI|WP_063842869.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	28.0	574	603	585	1.99e-67	229
k141_12840_24	NCBI|WP_001096376.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	28.0	579	603	585	2.77e-67	228
k141_12840_24	SARG|gb|ABV63006.2|ARO:3004759|BPU-1	32.6	233	603	262	4.82e-38	140
k141_12840_24	megares|MEG_1472|Drugs|beta-lactam|Class_D_betalactamases|BPU_1	32.6	233	603	262	4.82e-38	140
k141_12840_41	SARG|gi|500448961|gb|EOP61695.1|	29.6	216	246	306	1.55e-23	95.5
k141_12840_41	SARG|gi|446026113|ref|WP_000103968.1|	30.7	218	246	306	2.15e-23	95.1
k141_12840_41	SARG|gi|500465078|gb|EOP76697.1|	29.6	216	246	306	2.15e-23	95.1
k141_12840_41	SARG|gi|507044560|ref|WP_016115614.1|	30.3	218	246	306	1.10e-22	93.2
k141_12840_41	SARG|gi|445996719|ref|WP_000074574.1|	31.2	218	246	309	1.15e-22	93.2
k141_12840_41	SARG|gi|445996710|ref|WP_000074565.1|	30.4	217	246	309	4.24e-22	91.7
k141_12840_41	SARG|ABB80128	29.8	218	246	306	1.08e-21	90.5
k141_12840_41	SARG|P42332	30.8	185	246	306	1.45e-20	87.4
k141_12840_41	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	30.8	185	246	306	1.45e-20	87.4
k141_12840_41	SARG|gi|510143239|gb|AGN36970.1|	30.8	185	246	313	1.58e-20	87.4
k141_12840_46	SARG|U82085.gene.p01	20.6	538	515	552	2.93e-11	64.7
k141_12840_46	SARG|gb|WP_104671188.1|ARO:3003948|efrA	25.9	212	515	575	1.62e-10	62.4
k141_12840_46	SARG|gb|AAK76137.1|ARO:3000024|patA	20.4	211	515	564	3.18e-08	55.1
k141_12840_46	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	22.2	482	515	524	9.25e-08	53.5
k141_12840_46	SARG|gi|1033151784|ref|WP_064457526.1|	21.8	238	515	614	1.76e-07	52.8
k141_12840_46	SARG|gi|664304639|ref|WP_030834011.1|	21.8	238	515	614	1.76e-07	52.8
k141_12840_46	SARG|gi|1011069317|ref|WP_062010695.1|	21.8	238	515	614	1.76e-07	52.8
k141_12840_46	SARG|gi|987887954|ref|WP_060953374.1|	21.0	229	515	614	5.32e-07	51.2
k141_12840_46	SARG|gi|943938624|ref|WP_055567802.1|	20.7	237	515	602	6.96e-07	50.8
k141_12840_46	SARG|gi|930482089|ref|WP_054228897.1|	18.9	233	515	599	9.16e-07	50.4
k141_121163_18	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.5	220	225	219	2.84e-45	149
k141_121163_18	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.8	223	225	220	6.39e-38	130
k141_121163_18	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.8	223	225	220	9.02e-38	130
k141_121163_18	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.8	223	225	220	1.00e-36	127
k141_121163_18	CARD|gb|AAG06465.1|ARO:3005063|cprR	33.8	222	225	223	8.48e-36	125
k141_121163_18	SARG|ZP_02848503	31.4	223	225	221	4.92e-34	120
k141_121163_18	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	32.9	231	225	233	2.02e-32	116
k141_121163_18	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	35.2	236	225	252	1.33e-30	112
k141_121163_18	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	29.8	228	225	231	1.44e-27	103
k141_121163_18	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	32.9	231	225	232	1.12e-26	101
k141_121163_19	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	27.1	218	426	357	8.25e-19	86.3
k141_121163_19	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	27.1	218	426	357	8.25e-19	86.3
k141_121163_32	SARG|gi|403023847|gb|EJY36064.1|	38.3	180	401	200	4.56e-30	114
k141_121163_32	SARG|Q47746	38.9	180	401	268	1.21e-29	114
k141_121163_32	SARG|gi|452996213|gb|AGG19398.1|	38.9	180	401	268	1.21e-29	114
k141_121163_32	SARG|gi|403219412|emb|CCJ27774.1|	38.3	183	401	268	1.21e-29	114
k141_121163_32	SARG|gi|498515090|ref|WP_010815297.1|	38.9	180	401	268	1.21e-29	114
k141_121163_32	SARG|gi|452996227|gb|AGG19410.1|	38.3	180	401	252	1.62e-29	114
k141_121163_32	SARG|gi|488259314|ref|WP_002330522.1|	38.3	180	401	268	2.32e-29	114
k141_121163_32	SARG|gi|1036536100|emb|SAM71699.1|	38.3	180	401	268	2.32e-29	114
k141_121163_32	SARG|KF823969.1.gene3.p01	38.3	180	401	268	2.32e-29	114
k141_121163_32	SARG|FJ349556.1.gene4.p01	42.2	147	401	233	1.30e-25	102
k141_121163_34	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.1	291	479	365	1.02e-23	101
k141_121163_34	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	24.9	285	479	370	1.08e-23	101
k141_121163_34	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.5	333	479	381	1.68e-23	100
k141_121163_34	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.5	333	479	381	1.68e-23	100
k141_121163_34	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.3	332	479	381	3.08e-23	100
k141_121163_34	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.3	332	479	381	3.08e-23	100
k141_121163_34	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	32.6	261	479	381	4.17e-23	99.8
k141_121163_34	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	32.6	261	479	381	4.17e-23	99.8
k141_121163_34	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.6	333	479	381	1.40e-22	98.2
k141_121163_34	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.6	333	479	381	1.40e-22	98.2
k141_121163_35	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.2	225	221	232	6.17e-52	166
k141_121163_35	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.6	224	221	231	2.71e-50	162
k141_121163_35	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.1	218	221	220	2.85e-47	154
k141_121163_35	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.0	213	221	219	5.54e-47	153
k141_121163_35	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.1	218	221	220	8.06e-47	153
k141_121163_35	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.5	213	221	219	4.42e-46	151
k141_121163_35	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.4	218	221	219	7.04e-45	148
k141_121163_35	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.7	218	221	220	2.04e-44	147
k141_121163_35	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	38.5	218	221	228	3.61e-44	146
k141_121163_35	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.7	224	221	231	7.83e-44	145
k141_121163_41	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	21.6	348	397	397	6.47e-09	56.2
k141_121163_57	SARG|gb|APB03216.1|ARO:3003982|LlmA	59.6	285	288	287	2.64e-133	378
k141_19290_1	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	49.2	252	264	255	1.62e-84	252
k141_19290_1	SARG|gi|1035706844|ref|WP_064548272.1|	36.3	226	264	648	4.20e-43	154
k141_19290_1	SARG|gi|1035670474|ref|WP_064517458.1|	35.0	226	264	648	1.04e-41	150
k141_19290_1	SARG|gi|1035717981|ref|WP_064557480.1|	35.0	226	264	648	1.04e-41	150
k141_19290_1	SARG|gi|498115003|ref|WP_010429159.1|	36.7	226	264	646	1.41e-41	149
k141_19290_1	SARG|gi|746253210|ref|WP_039301529.1|	36.3	226	264	648	1.43e-41	149
k141_19290_1	SARG|gi|495736522|ref|WP_008461101.1|	36.3	226	264	648	1.97e-41	149
k141_19290_1	SARG|gi|746243059|ref|WP_039291473.1|	36.7	226	264	648	1.97e-41	149
k141_19290_1	SARG|gi|1001720867|ref|WP_061274204.1|	36.3	226	264	648	3.73e-41	148
k141_19290_1	SARG|gi|736472622|ref|WP_034494292.1|	34.5	226	264	648	3.73e-41	148
k141_19290_8	ResF|penA_1_AF515059_1	27.4	569	753	581	1.98e-44	167
k141_19290_9	ResF|penA_1_AF515059_1	26.3	566	599	581	4.35e-51	184
k141_19290_9	SARG|gb|AQX82857.1|ARO:3004185|mecD	23.6	576	599	678	3.50e-25	109
k141_19290_9	SARG|gb|BAI83385.1|ARO:3003440|mecB	22.9	584	599	674	6.54e-20	92.8
k141_19290_9	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	22.8	584	599	674	2.01e-19	91.3
k141_19290_9	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	23.1	385	599	593	1.45e-12	69.3
k141_19290_50	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.2	401	851	1197	1.95e-38	154
k141_19290_50	CARD|gb|ADM92605.1|ARO:3000553|adeR	34.1	129	851	247	6.80e-07	50.4
k141_19290_59	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.9	456	532	654	4.16e-31	126
k141_19290_59	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	25.9	456	532	670	4.42e-31	126
k141_19290_59	SARG|AAB51122	25.9	456	532	670	4.42e-31	126
k141_19290_59	SARG|Q08425	25.9	456	532	641	7.12e-31	125
k141_19290_59	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	25.9	456	532	657	7.59e-31	125
k141_19290_59	SARG|Z21523.gene.p01	25.9	456	532	657	7.59e-31	125
k141_19290_59	SARG|Q52360	25.4	453	532	641	2.31e-30	124
k141_19290_59	SARG|P70882	25.4	453	532	641	4.17e-30	123
k141_19290_59	SARG|BAD46890	25.4	453	532	657	4.43e-30	123
k141_19290_59	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.4	453	532	641	1.01e-29	122
k141_79439_12	SARG|gi|542061059|gb|ERI11611.1|	25.7	218	431	316	5.52e-16	77.4
k141_79439_12	SARG|gi|445996708|ref|WP_000074563.1|	28.9	228	431	309	2.28e-15	75.5
k141_79439_12	SARG|gi|445996710|ref|WP_000074565.1|	30.2	222	431	309	2.28e-15	75.5
k141_79439_12	SARG|gi|447195835|ref|WP_001273091.1|	26.8	220	431	306	2.97e-15	75.1
k141_79439_12	SARG|gi|447195836|ref|WP_001273092.1|	26.8	220	431	306	2.97e-15	75.1
k141_79439_12	SARG|gi|445996719|ref|WP_000074574.1|	28.4	208	431	309	4.13e-15	74.7
k141_79439_12	SARG|gi|445996732|ref|WP_000074587.1|	28.1	228	431	309	5.57e-15	74.3
k141_79439_12	SARG|gi|488130770|ref|WP_002201978.1|	28.1	228	431	309	5.57e-15	74.3
k141_79439_12	SARG|gi|445996696|ref|WP_000074551.1|	28.8	208	431	309	5.57e-15	74.3
k141_79439_12	SARG|gi|507035724|ref|WP_016107411.1|	28.8	208	431	309	7.49e-15	73.9
k141_121201_11	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	24.7	227	493	382	2.31e-21	94.7
k141_121201_11	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	24.7	227	493	382	2.31e-21	94.7
k141_121201_11	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	24.7	227	493	386	2.41e-21	94.7
k141_121201_11	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	24.7	227	493	386	2.41e-21	94.7
k141_121201_11	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	24.7	227	493	388	3.31e-21	94.4
k141_121201_11	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	24.7	227	493	388	3.31e-21	94.4
k141_121201_11	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	25.1	267	493	370	3.69e-21	94.0
k141_121201_11	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	24.2	227	493	384	1.41e-20	92.4
k141_121201_11	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	24.2	227	493	384	1.41e-20	92.4
k141_121201_11	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	24.2	227	493	386	1.44e-20	92.4
k141_121201_12	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	45.1	224	270	229	9.70e-58	183
k141_121201_12	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.8	225	270	232	8.49e-57	181
k141_121201_12	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.8	237	270	231	6.58e-56	178
k141_121201_12	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.0	224	270	231	9.31e-56	178
k141_121201_12	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	43.7	229	270	232	9.59e-56	178
k141_121201_12	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	43.7	229	270	233	9.88e-56	178
k141_121201_12	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.4	237	270	231	1.86e-55	177
k141_121201_12	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.4	237	270	231	2.63e-55	177
k141_121201_12	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	40.7	231	270	231	1.05e-54	175
k141_121201_12	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	42.6	235	270	235	1.18e-54	175
k141_12880_7	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	47.4	228	234	228	5.98e-68	207
k141_12880_7	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.2	225	234	231	2.71e-59	186
k141_12880_7	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.4	225	234	232	4.49e-58	182
k141_12880_7	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.5	228	234	232	2.90e-56	178
k141_12880_7	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.5	228	234	232	2.90e-56	178
k141_12880_7	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	41.5	234	234	233	4.23e-56	177
k141_12880_7	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.4	223	234	219	5.55e-56	177
k141_12880_7	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.1	232	234	232	2.33e-55	176
k141_12880_7	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.1	232	234	232	3.29e-55	175
k141_12880_7	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.2	232	234	231	9.05e-55	174
k141_12880_8	CARD|gb|AAD51347.1|ARO:3003067|smeS	29.4	269	473	467	1.49e-30	122
k141_12880_8	CARD|gb|CYF42523.1|ARO:3004047|kdpD	22.5	231	473	885	1.05e-11	66.2
k141_12880_22	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	31.4	338	507	373	1.97e-27	112
k141_12880_22	megares|MEG_7543|Drugs|Glycopeptide|VanG-type_accessory_protein|VANWG_1	29.3	123	507	281	4.49e-06	47.4
k141_12880_22	megares|MEG_7544|Drugs|Glycopeptide|VanG-type_accessory_protein|VANWG_1	29.3	123	507	281	4.49e-06	47.4
k141_12880_22	NCBI|WP_063856762.1|1|1|vanW-G|vanW-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-G|AMR|glycopeptide	29.3	123	507	281	4.49e-06	47.4
k141_12880_22	NCBI|WP_021419095.1|1|1|vanW-G|vanW-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-G|AMR|glycopeptide	29.3	123	507	281	4.49e-06	47.4
k141_12880_30	SARG|gi|740633514|ref|WP_038419019.1|	28.4	229	513	646	9.41e-21	94.7
k141_12880_30	SARG|gi|895898290|ref|WP_048999361.1|	28.4	229	513	646	9.41e-21	94.7
k141_12880_30	SARG|gi|895905590|ref|WP_049005458.1|	28.4	229	513	646	9.41e-21	94.7
k141_12880_30	SARG|gi|896083144|ref|WP_049122651.1|	28.4	229	513	646	9.41e-21	94.7
k141_12880_30	SARG|gi|765031087|ref|WP_044596899.1|	28.4	229	513	646	1.25e-20	94.4
k141_12880_30	SARG|gi|949731360|ref|WP_057072003.1|	28.4	229	513	646	1.25e-20	94.4
k141_12880_30	SARG|gi|835749851|ref|WP_047648187.1|	27.7	231	513	646	1.25e-20	94.4
k141_12880_30	SARG|gi|659669327|ref|WP_029883000.1|	28.4	229	513	646	1.25e-20	94.4
k141_12880_30	SARG|gi|498115003|ref|WP_010429159.1|	28.4	229	513	646	1.66e-20	94.0
k141_12880_30	SARG|gi|695748190|ref|WP_032674455.1|	27.9	229	513	646	2.21e-20	93.6
k141_12880_33	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.5	113	536	228	4.57e-10	58.9
k141_12880_33	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.0	116	536	204	2.20e-08	53.5
k141_12880_33	CARD|gb|AAG05188.1|ARO:3005068|ParR	27.4	113	536	235	3.39e-07	50.4
k141_12880_48	SARG|gi|507035724|ref|WP_016107411.1|	28.1	281	500	309	3.80e-24	101
k141_12880_48	SARG|gi|445996698|ref|WP_000074553.1|	31.2	231	500	309	3.80e-24	101
k141_12880_48	SARG|gi|445996719|ref|WP_000074574.1|	30.3	231	500	309	9.56e-24	100
k141_12880_48	SARG|gi|445996695|ref|WP_000074550.1|	28.5	281	500	309	1.30e-23	100
k141_12880_48	SARG|gi|445996696|ref|WP_000074551.1|	30.7	231	500	309	1.30e-23	100
k141_12880_48	SARG|gi|445996697|ref|WP_000074552.1|	30.7	231	500	309	1.77e-23	99.8
k141_12880_48	SARG|gi|445996710|ref|WP_000074565.1|	28.4	229	500	309	6.03e-23	98.2
k141_12880_48	SARG|gi|542061059|gb|ERI11611.1|	32.0	228	500	316	6.74e-23	98.2
k141_12880_48	SARG|gi|1043490477|ref|WP_065382463.1|	29.9	231	500	309	1.11e-22	97.4
k141_12880_48	SARG|gi|445996726|ref|WP_000074581.1|	29.9	231	500	309	1.11e-22	97.4
k141_25352_21	SARG|gb|AAK76137.1|ARO:3000024|patA	24.9	213	506	564	6.23e-10	60.5
k141_25352_21	SARG|gi|928900436|ref|WP_053931243.1|	23.7	435	506	600	7.94e-09	57.0
k141_25352_21	SARG|gi|664579989|ref|WP_031094015.1|	23.7	435	506	601	7.95e-09	57.0
k141_25352_21	SARG|gi|171851258|emb|CAQ04234.1|	50.0	54	506	483	9.10e-09	56.6
k141_25352_21	SARG|gi|648667297|ref|WP_026359044.1|	22.1	429	506	605	4.23e-08	54.7
k141_25352_21	SARG|gi|736993687|ref|WP_034989673.1|	48.1	54	506	513	5.08e-08	54.3
k141_25352_21	SARG|AF024666.2.gene6.p01	48.1	54	506	513	5.08e-08	54.3
k141_25352_21	SARG|AF170880.4.gene1.p01	22.0	432	506	615	9.80e-08	53.5
k141_25352_21	SARG|gi|948137056|ref|WP_056795395.1|	23.2	426	506	602	1.28e-07	53.1
k141_25352_21	SARG|gi|558888514|ref|WP_023543283.1|	22.0	432	506	615	1.71e-07	52.8
k141_73267_10	SARG|gb|BAG33043.1|ARO:3003920|pgpB	33.9	174	179	236	1.42e-14	68.2
k141_73267_10	megares|MEG_5776|Drugs|Lipopeptide|Lipid_A_phosphatase|PGBB_1	33.9	174	179	236	1.42e-14	68.2
k141_73267_31	SARG|gi|542061059|gb|ERI11611.1|	46.5	301	313	316	1.58e-91	274
k141_73267_31	SARG|gi|447057509|ref|WP_001134765.1|	45.3	298	313	309	1.02e-90	271
k141_73267_31	SARG|gi|507055561|ref|WP_016126482.1|	45.3	298	313	309	2.89e-90	270
k141_73267_31	SARG|gi|488053456|ref|WP_002124853.1|	45.3	298	313	309	2.89e-90	270
k141_73267_31	SARG|gi|446110087|ref|WP_000187942.1|	45.6	298	313	309	4.10e-90	270
k141_73267_31	SARG|gi|445996714|ref|WP_000074569.1|	45.6	298	313	309	4.10e-90	270
k141_73267_31	SARG|gi|488068784|ref|WP_002140181.1|	45.3	298	313	309	4.10e-90	270
k141_73267_31	SARG|gi|447057510|ref|WP_001134766.1|	45.7	300	313	309	5.80e-90	270
k141_73267_31	SARG|gi|814314593|emb|CKF49145.1|	45.6	298	313	309	5.80e-90	270
k141_73267_31	SARG|gi|895808656|emb|COR83787.1|	45.6	298	313	309	5.80e-90	270
k141_73267_32	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	27.9	276	316	392	1.12e-28	112
k141_73267_32	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.1	253	316	365	1.47e-28	112
k141_73267_32	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.6	271	316	381	5.63e-25	102
k141_73267_32	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.6	271	316	381	5.63e-25	102
k141_73267_32	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	24.9	289	316	368	9.13e-25	101
k141_73267_32	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.3	262	316	370	9.35e-25	101
k141_73267_32	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	23.7	270	316	381	1.06e-24	101
k141_73267_32	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	23.7	270	316	381	1.06e-24	101
k141_73267_32	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.6	271	316	381	1.46e-24	101
k141_73267_32	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.6	271	316	381	1.46e-24	101
k141_73267_33	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.9	229	234	231	8.37e-61	189
k141_73267_33	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.1	228	234	232	8.63e-61	189
k141_73267_33	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	36.2	229	234	231	3.98e-56	177
k141_73267_33	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	36.3	234	234	235	6.35e-56	177
k141_73267_33	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	34.8	230	234	233	8.46e-56	177
k141_73267_33	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.3	227	234	232	1.64e-55	176
k141_73267_33	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.3	227	234	232	1.64e-55	176
k141_73267_33	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	37.4	230	234	239	2.86e-55	176
k141_73267_33	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	36.7	229	234	230	3.52e-54	172
k141_73267_33	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.3	225	234	231	2.05e-53	171
k141_73267_38	SARG|gb|CAE00499.1|ARO:3003835|cdeA	33.1	472	478	441	2.81e-84	265
k141_79832_8	SARG|gb|AAK76136.1|ARO:3000025|patB	33.2	605	643	588	6.69e-104	326
k141_79832_8	SARG|gb|AYV52072.1|ARO:3002882|lmrD	31.6	545	643	664	1.49e-89	291
k141_79832_8	SARG|gi|497748188|ref|WP_010062372.1|	31.5	607	643	605	8.68e-86	279
k141_79832_8	SARG|gi|951183771|ref|WP_057661487.1|	32.0	590	643	603	1.62e-85	278
k141_79832_8	SARG|gi|695891735|ref|WP_032792824.1|	32.0	590	643	603	2.26e-85	278
k141_79832_8	SARG|gi|664180077|ref|WP_030714054.1|	31.5	607	643	605	4.65e-85	277
k141_79832_8	SARG|gi|695887424|ref|WP_032788534.1|	31.3	604	643	605	6.50e-85	277
k141_79832_8	SARG|gi|913055317|ref|WP_050357634.1|	31.9	590	643	603	8.67e-85	276
k141_79832_8	SARG|gi|948040364|ref|WP_056699531.1|	31.9	590	643	603	1.70e-84	276
k141_79832_8	SARG|gi|827013130|ref|WP_047175495.1|	32.0	591	643	603	1.70e-84	276
k141_79832_9	SARG|gb|WP_104671188.1|ARO:3003948|efrA	34.4	543	584	575	1.25e-100	315
k141_79832_9	SARG|gb|AAK76137.1|ARO:3000024|patA	33.6	569	584	564	6.53e-97	305
k141_79832_9	SARG|gb|AYV52072.1|ARO:3002882|lmrD	31.0	464	584	664	1.48e-61	214
k141_79832_9	SARG|gb|AAK76136.1|ARO:3000025|patB	31.1	466	584	588	4.73e-56	197
k141_79832_9	SARG|gi|1045390184|ref|WP_065479071.1|	28.0	540	584	605	6.32e-56	197
k141_79832_9	SARG|gb|CDO61516.1|ARO:3003949|efrB	34.0	332	584	362	9.34e-56	191
k141_79832_9	SARG|gi|497748188|ref|WP_010062372.1|	27.2	540	584	605	3.04e-54	193
k141_79832_9	SARG|gi|695865802|ref|WP_032778631.1|	27.2	540	584	605	7.99e-54	192
k141_79832_9	SARG|gi|517381192|ref|WP_018555350.1|	27.7	549	584	602	1.05e-53	191
k141_79832_9	SARG|gi|664180077|ref|WP_030714054.1|	27.0	540	584	605	2.89e-53	190
k141_79832_14	SARG|ZP_04528247	67.9	277	276	279	1.02e-125	358
k141_79832_14	SARG|ZP_03958019	65.2	279	276	317	2.16e-124	356
k141_79832_14	SARG|YP_002929946	67.5	280	276	282	1.07e-123	353
k141_79832_14	SARG|YP_002937728	66.2	278	276	289	5.21e-121	346
k141_79832_14	SARG|ZP_03984017	56.5	269	276	288	9.64e-102	297
k141_79832_14	SARG|ZP_04433866	56.5	269	276	288	1.94e-101	296
k141_79832_14	SARG|ZP_03949893	56.5	269	276	288	1.94e-101	296
k141_79832_14	SARG|ZP_03938934	55.6	277	276	288	4.21e-93	275
k141_79832_14	SARG|ZP_03941859	55.2	277	276	288	1.70e-92	274
k141_79832_14	SARG|ZP_03945515	53.8	277	276	291	9.96e-90	267
k141_79832_22	SARG|gi|446048047|ref|WP_000125902.1|	25.3	253	509	648	3.13e-15	77.4
k141_79832_22	SARG|gi|446048048|ref|WP_000125903.1|	25.3	253	509	648	4.14e-15	77.0
k141_79832_22	SARG|gi|555222481|ref|WP_023215070.1|	25.4	252	509	648	5.49e-15	76.6
k141_79832_22	SARG|gi|923061916|ref|WP_053445667.1|	25.2	246	509	648	5.49e-15	76.6
k141_79832_22	SARG|gi|554689873|ref|WP_023186409.1|	26.2	237	509	648	7.27e-15	76.3
k141_79832_22	SARG|YP_001588793	25.2	246	509	648	7.27e-15	76.3
k141_79832_22	SARG|gi|555246906|ref|WP_023230855.1|	25.0	252	509	648	9.62e-15	75.9
k141_79832_22	SARG|gi|970558766|ref|WP_058820271.1|	25.0	252	509	648	9.62e-15	75.9
k141_79832_22	SARG|gi|446048045|ref|WP_000125900.1|	25.0	252	509	648	9.62e-15	75.9
k141_79832_22	SARG|gi|555241715|ref|WP_023226297.1|	25.0	252	509	648	9.62e-15	75.9
k141_55498_10	CARD|gb|AGV28567.1|ARO:3000559|adeN	44.0	50	218	217	2.59e-07	48.5
k141_55498_10	NCBI|ACF30254.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	31.4	102	218	210	2.83e-06	45.4
k141_55498_10	NCBI|CAA81047.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	32.1	84	218	210	5.19e-06	44.7
k141_55498_11	NCBI|WP_070509550.1|1|1|mef(H)|mef(H)|efflux|2|ERYTHROMYCIN|MACROLIDE|macrolide_efflux_MFS_transporter_Mef(H)|AMR|macrolide	48.0	410	412	412	5.74e-123	361
k141_55498_11	SARG|gb|QQM99829.1|ARO:3007047|mefH	41.0	105	412	109	1.10e-18	80.1
k141_55498_11	CARD|gb|ABV18113.1|ARO:3001329|mdtG	31.9	160	412	408	5.52e-10	59.7
k141_55498_11	SARG|AF030344.gene.p01	23.7	152	412	419	6.78e-07	50.1
k141_55498_11	megares|MEG_7205|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|TETV_1	23.7	152	412	419	6.78e-07	50.1
k141_55498_11	SARG|gi|906298254|emb|CRZ18264.1|	24.2	153	412	429	6.90e-07	50.1
k141_55498_11	SARG|gi|518176507|ref|WP_019346715.1|	23.4	154	412	426	6.53e-06	47.0
k141_37817_10	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.5	174	306	231	2.61e-20	86.7
k141_37817_10	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	35.5	138	306	230	4.71e-19	83.2
k141_37817_10	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	38.0	121	306	235	4.88e-18	80.5
k141_37817_10	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	30.7	176	306	233	1.70e-17	79.0
k141_37817_10	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.5	121	306	231	2.26e-17	78.6
k141_37817_10	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.5	121	306	231	3.10e-17	78.2
k141_37817_10	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.5	121	306	231	4.27e-17	77.8
k141_37817_10	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.7	121	306	231	8.08e-17	77.0
k141_37817_10	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	32.8	119	306	231	1.74e-14	70.5
k141_37817_10	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.1	121	306	231	6.08e-14	68.9
k141_37817_14	SARG|gb|AAK76137.1|ARO:3000024|patA	21.1	218	517	564	2.42e-08	55.5
k141_37817_14	SARG|gi|817122037|ref|WP_046494699.1|	24.9	233	517	613	1.77e-07	52.8
k141_37817_14	SARG|gi|663350985|ref|WP_030349761.1|	25.4	232	517	613	9.31e-07	50.4
k141_37817_14	SARG|gi|860594225|ref|WP_048475168.1|	23.5	238	517	620	3.73e-06	48.5
k141_37817_14	SARG|gi|748767925|ref|WP_040019608.1|	25.1	247	517	623	4.93e-06	48.1
k141_37817_14	SARG|gi|926351744|ref|WP_053683383.1|	23.5	238	517	648	5.01e-06	48.1
k141_37817_14	SARG|gi|926400371|ref|WP_053728483.1|	23.8	240	517	603	6.42e-06	47.8
k141_37817_14	SARG|gi|948137056|ref|WP_056795395.1|	23.7	232	517	602	8.46e-06	47.4
k141_37817_14	SARG|gi|505420018|ref|WP_015607120.1|	23.8	235	517	603	8.46e-06	47.4
k141_37817_21	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	71.0	231	233	231	7.92e-124	349
k141_37817_21	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	70.1	231	233	231	2.27e-123	348
k141_37817_21	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	70.6	231	233	231	9.22e-123	347
k141_37817_21	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	69.3	231	233	231	4.36e-121	342
k141_37817_21	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	68.8	231	233	231	1.25e-120	341
k141_37817_21	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	64.5	231	233	232	1.58e-114	326
k141_37817_21	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	64.1	231	233	232	4.53e-114	325
k141_37817_21	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	57.4	235	233	233	2.38e-95	277
k141_37817_21	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	56.6	235	233	235	8.41e-94	273
k141_37817_21	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	56.7	233	233	232	4.13e-91	266
k141_37817_22	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	52.0	369	379	386	5.69e-121	354
k141_37817_22	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	52.0	369	379	386	5.69e-121	354
k141_37817_22	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	52.8	369	379	384	7.54e-121	353
k141_37817_22	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	52.8	369	379	384	7.54e-121	353
k141_37817_22	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	52.0	369	379	386	3.71e-119	349
k141_37817_22	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	52.0	369	379	386	3.71e-119	349
k141_37817_22	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	52.0	369	379	382	7.48e-118	346
k141_37817_22	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	52.0	369	379	382	7.48e-118	346
k141_37817_22	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	55.0	329	379	388	7.34e-117	343
k141_37817_22	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	55.0	329	379	388	7.34e-117	343
k141_37817_23	SARG|DQ212986.1.gene8.p01	55.1	341	366	349	3.89e-134	385
k141_37817_23	SARG|gi|405945042|pdb|4FU0|A	55.1	341	366	357	5.11e-134	385
k141_37817_23	SARG|gi|765411304|ref|WP_044689514.1|	55.1	341	366	349	7.82e-134	385
k141_37817_23	SARG|AAF71281	54.8	341	366	349	2.23e-133	384
k141_37817_23	SARG|gi|1028100561|ref|WP_063856696.1|	54.1	342	366	349	7.32e-132	380
k141_37817_23	SARG|gi|752682279|ref|WP_041330231.1|	54.4	342	366	349	1.04e-131	379
k141_37817_23	NCBI|PBI24747.1|1|1|vanG-Cd|vanG-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--D-serine_ligase_VanG-Cd|AMR|glycopeptide	53.9	360	366	366	7.47e-131	378
k141_37817_23	NCBI|WP_015943583.1|1|1|vanI|vanI|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanI|AMR|glycopeptide	45.2	347	366	341	1.25e-97	292
k141_37817_23	SARG|ACQ66105	46.3	350	366	342	1.29e-97	292
k141_37817_23	SARG|gi|748291566|ref|WP_039833224.1|	44.6	350	366	343	3.77e-97	291
k141_37817_24	NCBI|WP_063856783.1|1|1|vanXY-G2|vanXY-G2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-G2|AMR|glycopeptide	43.0	265	273	254	8.10e-69	212
k141_37817_24	NCBI|WP_063856782.1|1|1|vanXY-G|vanXY-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-G|AMR|glycopeptide	42.3	265	273	254	1.85e-67	209
k141_37817_24	NCBI|WP_063856817.1|1|1|vanXY-L|vanXY-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-L|AMR|glycopeptide	43.4	182	273	193	1.48e-42	143
k141_37817_24	NCBI|WP_003126779.1|1|1|vanXY-C|vanXY-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	42.7	185	273	190	2.70e-42	142
k141_37817_24	ResF|VanLXY_1_EU250284_2	48.3	151	273	167	4.30e-41	138
k141_37817_24	NCBI|WP_008377360.1|1|1|vanXY-c4|vanXY-c4|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	44.4	153	273	190	1.19e-40	138
k141_37817_24	NCBI|WP_063856805.1|1|1|vanXY-C|vanXY-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	45.1	153	273	190	1.19e-40	138
k141_37817_24	NCBI|WP_010749757.1|1|1|vanXY-C|vanXY-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	44.4	153	273	190	2.36e-40	137
k141_37817_24	NCBI|WP_063856795.1|1|1|vanXY-c4|vanXY-c4|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	44.4	153	273	190	3.33e-40	137
k141_37817_24	NCBI|WP_060792852.1|1|1|vanXY-c2/3|vanXY-c2/3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	44.4	153	273	190	4.69e-40	136
k141_37817_25	SARG|gb|ABA71733.1|ARO:3002972|vanTG	43.4	758	771	712	8.94e-205	595
k141_37817_25	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	41.3	761	771	712	8.75e-191	559
k141_37817_25	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	39.3	761	771	711	3.34e-166	496
k141_37817_25	SARG|FJ872411.1.gene43.p01	35.8	759	771	702	2.93e-141	431
k141_37817_25	SARG|gi|498467693|ref|WP_010773049.1|	35.6	761	771	700	5.13e-138	422
k141_37817_25	SARG|JF802084.2.gene3.p01	35.0	762	771	700	9.48e-131	404
k141_37817_25	SARG|AF162694.1.gene4.p01	33.4	757	771	698	1.41e-120	377
k141_37817_25	SARG|gi|657686198|ref|WP_029487032.1|	33.4	757	771	698	2.77e-120	376
k141_37817_25	SARG|AAY67970	33.2	756	771	698	2.12e-119	374
k141_37817_25	megares|MEG_7535|Drugs|Glycopeptide|VanN-type_resistance_protein|VANTN_1	35.1	683	771	656	3.51e-115	362
k141_37817_28	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.4	123	133	232	8.05e-21	83.2
k141_37817_28	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.4	123	133	232	8.05e-21	83.2
k141_37817_28	CARD|gb|AAC73788.1|ARO:3003841|kdpE	38.6	114	133	225	2.21e-18	76.6
k141_37817_28	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	34.4	128	133	235	2.59e-18	76.6
k141_37817_28	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	38.7	111	133	225	6.05e-18	75.5
k141_37817_28	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	40.8	103	133	239	2.05e-17	74.3
k141_37817_28	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	114	133	219	2.11e-17	73.9
k141_37817_28	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	114	133	219	2.11e-17	73.9
k141_37817_28	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	114	133	220	2.14e-17	73.9
k141_37817_28	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	114	133	220	2.99e-17	73.6
k141_127400_1	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	64.5	62	69	307	3.16e-20	80.1
k141_127400_1	SARG|gi|500194536|ref|WP_011867743.1|	50.7	67	69	306	1.12e-15	67.8
k141_127400_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	38.2	220	234	228	1.36e-50	163
k141_127400_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.6	227	234	232	2.44e-49	160
k141_127400_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.6	227	234	232	2.44e-49	160
k141_127400_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.3	226	234	231	4.24e-47	154
k141_127400_2	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.4	226	234	231	5.99e-47	154
k141_127400_2	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.4	226	234	231	8.46e-47	154
k141_127400_2	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.2	227	234	231	1.20e-46	153
k141_127400_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.1	232	234	235	3.77e-46	152
k141_127400_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	38.1	226	234	229	6.35e-46	151
k141_127400_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	37.4	230	234	233	7.11e-46	151
k141_127400_3	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	24.1	282	486	364	1.11e-15	77.4
k141_127400_3	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	24.1	282	486	364	1.11e-15	77.4
k141_127400_3	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	20.9	215	486	381	5.42e-14	72.4
k141_127400_3	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	20.9	215	486	381	5.42e-14	72.4
k141_127400_3	CARD|gb|CYF42523.1|ARO:3004047|kdpD	26.4	220	486	885	1.28e-13	72.4
k141_127400_3	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	20.2	267	486	359	1.52e-12	67.8
k141_127400_3	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	21.5	251	486	354	1.97e-12	67.4
k141_127400_3	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	22.7	256	486	354	3.51e-12	66.6
k141_127400_3	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	21.1	251	486	352	1.96e-11	64.3
k141_127400_3	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	21.1	251	486	376	2.21e-11	64.3
k141_8137_4	SARG|P42332	28.1	221	510	306	1.45e-20	91.3
k141_8137_4	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	28.1	221	510	306	1.45e-20	91.3
k141_8137_4	SARG|gi|510143239|gb|AGN36970.1|	28.1	221	510	313	1.61e-20	91.3
k141_8137_4	SARG|ABB80128	28.1	221	510	306	2.66e-20	90.5
k141_8137_4	SARG|AAD21213	27.6	221	510	306	8.89e-20	89.0
k141_8137_4	SARG|gb|AAK76137.1|ARO:3000024|patA	22.5	213	510	564	1.66e-07	52.8
k141_8137_4	SARG|gi|498397844|ref|WP_010711245.1|	24.6	191	510	498	2.49e-06	48.9
k141_8137_4	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	21.9	389	510	461	3.15e-06	48.5
k141_8137_4	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	21.4	369	510	461	3.15e-06	48.5
k141_8137_4	SARG|gi|895819918|ref|WP_048943810.1|	24.6	191	510	498	7.59e-06	47.4
k141_103787_13	SARG|gi|507044560|ref|WP_016115614.1|	41.3	206	234	306	4.56e-42	144
k141_103787_13	SARG|gi|542061059|gb|ERI11611.1|	39.1	215	234	316	1.14e-41	143
k141_103787_13	SARG|gi|446026113|ref|WP_000103968.1|	40.8	206	234	306	3.54e-41	141
k141_103787_13	SARG|gi|445996719|ref|WP_000074574.1|	40.3	206	234	309	1.05e-40	140
k141_103787_13	SARG|gi|447195835|ref|WP_001273091.1|	40.0	215	234	306	2.74e-40	139
k141_103787_13	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	37.5	216	234	307	3.94e-40	139
k141_103787_13	SARG|gi|447195836|ref|WP_001273092.1|	39.5	215	234	306	7.60e-40	138
k141_103787_13	SARG|gi|500194536|ref|WP_011867743.1|	41.7	206	234	306	1.07e-39	137
k141_103787_13	SARG|P42332	41.7	206	234	306	1.50e-39	137
k141_103787_13	SARG|ZP_04081918	40.8	206	234	306	1.50e-39	137
k141_103787_16	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	40.9	220	223	223	5.07e-52	166
k141_103787_16	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	32.7	226	223	232	5.57e-35	123
k141_103787_16	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	32.7	226	223	232	5.57e-35	123
k141_103787_16	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	32.3	226	223	231	1.08e-34	122
k141_103787_16	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.3	226	223	231	1.08e-34	122
k141_103787_16	CARD|gb|AAD51348.1|ARO:3003066|smeR	36.3	223	223	229	4.03e-34	120
k141_103787_16	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.9	224	223	231	8.40e-34	120
k141_103787_16	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.3	226	223	231	1.18e-33	119
k141_103787_16	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	31.9	226	223	231	1.18e-33	119
k141_103787_16	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.5	220	223	228	2.17e-33	119
k141_103787_17	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	29.2	281	337	341	6.19e-43	150
k141_103787_18	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	52.4	252	253	255	8.60e-94	275
k141_103787_18	SARG|gi|391288090|gb|EIQ46599.1|	39.3	219	253	645	3.38e-47	164
k141_103787_18	SARG|gi|823326845|ref|WP_047080664.1|	38.8	219	253	648	9.22e-47	163
k141_103787_18	SARG|YP_309843	38.8	219	253	648	9.22e-47	163
k141_103787_18	SARG|gi|823302270|ref|WP_047057473.1|	38.8	219	253	648	9.22e-47	163
k141_103787_18	SARG|gi|976146774|ref|WP_059305359.1|	38.8	219	253	648	9.22e-47	163
k141_103787_18	SARG|gi|1022664304|ref|WP_063420886.1|	38.8	219	253	648	9.22e-47	163
k141_103787_18	SARG|gi|823309640|ref|WP_047064288.1|	38.8	219	253	648	9.22e-47	163
k141_103787_18	SARG|gi|920465160|ref|WP_052991191.1|	38.8	219	253	648	9.22e-47	163
k141_103787_18	SARG|gi|505807117|ref|WP_015704872.1|	38.8	219	253	648	9.22e-47	163
k141_115428_5	SARG|gi|695865802|ref|WP_032778631.1|	33.8	284	595	605	3.22e-42	159
k141_115428_5	SARG|gi|1045390184|ref|WP_065479071.1|	33.8	284	595	605	3.22e-42	159
k141_115428_5	SARG|gi|764446018|ref|WP_044369325.1|	33.8	284	595	605	4.38e-42	159
k141_115428_5	SARG|gi|695842130|ref|WP_032755430.1|	34.2	284	595	603	5.84e-42	159
k141_115428_5	SARG|gi|505420018|ref|WP_015607120.1|	34.2	284	595	603	5.84e-42	159
k141_115428_5	SARG|gi|748767925|ref|WP_040019608.1|	32.1	308	595	623	7.24e-42	159
k141_115428_5	SARG|gi|496018010|ref|WP_008742581.1|	32.8	308	595	623	7.24e-42	159
k141_115428_5	SARG|gi|695887424|ref|WP_032788534.1|	33.8	284	595	605	8.13e-42	158
k141_115428_5	SARG|gi|664180077|ref|WP_030714054.1|	33.8	284	595	605	8.13e-42	158
k141_115428_5	SARG|gi|663350985|ref|WP_030349761.1|	32.8	296	595	613	1.21e-41	158
k141_115428_6	SARG|gi|748767925|ref|WP_040019608.1|	32.0	338	607	623	3.33e-40	154
k141_115428_6	SARG|gi|663350985|ref|WP_030349761.1|	31.6	339	607	613	1.17e-38	149
k141_115428_6	SARG|gi|1011069317|ref|WP_062010695.1|	32.0	350	607	614	2.17e-38	149
k141_115428_6	SARG|gi|1033151784|ref|WP_064457526.1|	32.0	350	607	614	2.93e-38	148
k141_115428_6	SARG|gi|987887954|ref|WP_060953374.1|	32.0	350	607	614	2.93e-38	148
k141_115428_6	SARG|gi|664304639|ref|WP_030834011.1|	32.0	350	607	614	2.93e-38	148
k141_115428_6	SARG|gi|943909899|ref|WP_055545300.1|	32.5	308	607	601	6.46e-38	147
k141_115428_6	SARG|gi|943938624|ref|WP_055567802.1|	32.8	308	607	602	6.52e-38	147
k141_115428_6	SARG|gi|655401130|ref|WP_028800283.1|	31.1	338	607	599	1.16e-37	146
k141_115428_6	SARG|gi|928900436|ref|WP_053931243.1|	31.2	333	607	600	1.59e-37	146
k141_115428_32	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	47.5	219	225	223	4.89e-71	215
k141_115428_32	CARD|gb|ATC67679.1|ARO:3000838|arlR	33.2	220	225	219	2.14e-35	124
k141_115428_32	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.4	220	225	219	9.28e-34	119
k141_115428_32	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.4	220	225	219	1.31e-33	119
k141_115428_32	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.4	220	225	220	1.34e-33	119
k141_115428_32	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.4	220	225	220	1.89e-33	119
k141_115428_32	SARG|ZP_02848503	31.8	220	225	221	2.73e-33	118
k141_115428_32	CARD|gb|AAD51348.1|ARO:3003066|smeR	31.5	219	225	229	4.68e-33	118
k141_115428_32	CARD|gb|AAG05188.1|ARO:3005068|ParR	29.3	222	225	235	5.91e-32	115
k141_115428_32	CARD|gb|AAC73788.1|ARO:3003841|kdpE	29.6	223	225	225	1.29e-31	114
k141_115428_33	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	38.1	310	340	341	1.43e-55	183
k141_115428_34	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	49.8	247	280	255	3.29e-83	249
k141_115428_34	SARG|gi|960873409|ref|WP_058345546.1|	38.8	232	280	648	2.43e-52	179
k141_115428_34	SARG|YP_001571041	40.1	222	280	648	4.69e-52	179
k141_115428_34	SARG|gi|740610794|ref|WP_038396317.1|	38.4	232	280	648	9.04e-52	178
k141_115428_34	SARG|gi|545248218|ref|WP_021546584.1|	40.5	222	280	648	6.45e-51	176
k141_115428_34	SARG|gi|922960663|ref|WP_053388845.1|	41.7	218	280	648	6.45e-51	176
k141_115428_34	SARG|gi|757799695|ref|WP_043016897.1|	41.7	218	280	648	8.94e-51	175
k141_115428_34	SARG|gi|1045891604|ref|WP_065554100.1|	41.7	218	280	648	8.94e-51	175
k141_115428_34	SARG|gi|507082903|ref|WP_016153652.1|	41.7	218	280	648	8.94e-51	175
k141_115428_34	SARG|gi|740856590|ref|WP_038641842.1|	41.7	218	280	648	8.94e-51	175
k141_115428_67	SARG|gi|542061059|gb|ERI11611.1|	29.6	233	513	316	1.14e-18	85.9
k141_115428_67	SARG|gi|445996722|ref|WP_000074577.1|	28.3	240	513	309	6.26e-18	83.6
k141_115428_67	SARG|gi|445996723|ref|WP_000074578.1|	27.9	240	513	309	8.43e-18	83.2
k141_115428_67	SARG|gi|445996719|ref|WP_000074574.1|	27.9	240	513	309	1.14e-17	82.8
k141_115428_67	SARG|gi|445996724|ref|WP_000074579.1|	28.3	240	513	309	1.14e-17	82.8
k141_115428_67	SARG|gi|884875933|emb|CKG93789.1|	28.3	240	513	309	1.14e-17	82.8
k141_115428_67	SARG|gi|1043490477|ref|WP_065382463.1|	27.9	240	513	309	1.53e-17	82.4
k141_115428_67	SARG|gi|445996726|ref|WP_000074581.1|	27.9	240	513	309	1.53e-17	82.4
k141_115428_67	SARG|gi|447057509|ref|WP_001134765.1|	27.5	240	513	309	1.53e-17	82.4
k141_115428_67	SARG|gi|507054395|ref|WP_016125339.1|	27.9	240	513	309	1.53e-17	82.4
k141_115428_97	SARG|gi|1031833294|ref|WP_064159420.1|	32.2	202	515	646	1.75e-22	100
k141_115428_97	SARG|gi|501015807|ref|WP_012068502.1|	31.7	202	515	646	1.75e-22	100
k141_115428_97	SARG|gi|490320210|ref|WP_004209695.1|	31.7	202	515	646	3.10e-22	99.4
k141_115428_97	SARG|gi|927316447|ref|WP_053810605.1|	31.4	207	515	646	3.10e-22	99.4
k141_115428_97	SARG|gi|782700886|ref|WP_045611431.1|	31.7	202	515	646	3.10e-22	99.4
k141_115428_97	SARG|gi|852292746|ref|WP_048332551.1|	31.7	202	515	646	3.10e-22	99.4
k141_115428_97	SARG|gi|895895864|ref|WP_048997630.1|	31.7	202	515	644	4.11e-22	99.0
k141_115428_97	SARG|gi|1031835425|ref|WP_064161077.1|	31.7	202	515	646	4.13e-22	99.0
k141_115428_97	SARG|gi|1031822889|ref|WP_064150402.1|	31.7	202	515	646	4.13e-22	99.0
k141_115428_97	SARG|gi|490306253|ref|WP_004201358.1|	31.7	202	515	646	4.13e-22	99.0
k141_115428_108	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	43.1	1052	1056	1033	0.0	922
k141_115428_108	SARG|gb|AEY83581|ARO:3000510|mupB	43.1	1052	1056	1033	0.0	922
k141_115428_108	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	43.2	1025	1056	1024	3.58e-318	907
k141_115428_108	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	43.2	1025	1056	1024	3.58e-318	907
k141_115428_108	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	42.9	1025	1056	1024	2.63e-315	899
k141_115428_108	SARG|gb|CAA53189|ARO:3000521|mupA	42.9	1025	1056	1024	2.63e-315	899
k141_115428_108	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	36.4	1082	1056	1107	1.40e-217	651
k141_115428_108	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	36.4	1082	1056	1107	1.40e-217	651
k141_115428_116	SARG|gb|MBY8651253.1|ARO:3007189|vanP	30.2	368	363	342	8.30e-44	153
k141_115428_117	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	38.1	464	461	481	8.95e-89	278
k141_115428_117	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	37.0	460	461	451	4.25e-88	275
k141_115428_117	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.7	462	461	451	3.33e-87	273
k141_115428_172	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.1	110	525	219	2.23e-06	47.8
k141_115428_173	SARG|gi|921979807|ref|WP_053271336.1|	26.9	223	507	648	1.76e-15	78.2
k141_115428_173	SARG|gb|APB03219.1|ARO:3003986|TaeA	21.8	510	507	648	4.82e-13	70.5
k141_115428_173	SARG|gi|446110334|ref|WP_000188189.1|	26.9	212	507	648	1.48e-12	68.9
k141_115428_173	SARG|gi|488120365|ref|WP_002191762.1|	26.9	212	507	309	3.86e-10	60.1
k141_115428_173	SARG|gi|445996710|ref|WP_000074565.1|	26.9	216	507	309	3.86e-10	60.1
k141_115428_173	SARG|gi|507055561|ref|WP_016126482.1|	26.4	212	507	309	5.16e-10	59.7
k141_115428_173	SARG|gi|507023808|ref|WP_016095885.1|	26.4	212	507	309	5.16e-10	59.7
k141_115428_173	SARG|gi|447057509|ref|WP_001134765.1|	26.4	212	507	309	5.16e-10	59.7
k141_115428_173	SARG|gi|488068784|ref|WP_002140181.1|	25.9	212	507	309	6.90e-10	59.3
k141_115428_173	SARG|gi|488067981|ref|WP_002139378.1|	26.4	212	507	309	9.21e-10	58.9
k141_97721_3	SARG|gi|542061059|gb|ERI11611.1|	36.3	311	350	316	8.89e-49	165
k141_97721_3	SARG|gi|447195835|ref|WP_001273091.1|	43.2	213	350	306	7.41e-48	162
k141_97721_3	SARG|gi|447195836|ref|WP_001273092.1|	42.7	213	350	306	2.05e-47	161
k141_97721_3	SARG|ZP_04081918	42.7	213	350	306	2.88e-47	161
k141_97721_3	SARG|YP_001373621	40.7	221	350	318	5.48e-47	160
k141_97721_3	SARG|AAD21213	34.6	312	350	306	7.98e-47	160
k141_97721_3	SARG|P42332	34.7	311	350	306	2.21e-46	159
k141_97721_3	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	34.7	311	350	306	2.21e-46	159
k141_97721_3	SARG|gi|510143239|gb|AGN36970.1|	34.7	311	350	313	2.63e-46	159
k141_97721_3	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	41.2	221	350	307	3.18e-46	158
k141_103886_2	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	34.1	223	252	325	6.71e-36	129
k141_103886_2	SARG|gb|AAA26793|ARO:3003748|oleC	34.4	218	252	325	1.84e-35	127
k141_103886_2	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	35.6	205	252	293	2.43e-30	113
k141_103886_2	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	33.3	222	252	293	7.11e-28	107
k141_103886_2	SARG|gi|736993687|ref|WP_034989673.1|	37.3	59	252	513	6.00e-06	45.8
k141_103886_2	SARG|AF024666.2.gene6.p01	37.3	59	252	513	6.00e-06	45.8
k141_103886_2	SARG|gi|171851258|emb|CAQ04234.1|	35.6	59	252	483	7.85e-06	45.4
k141_103886_7	CARD|gb|AEX49906.1|ARO:3003583|basS	29.3	328	466	477	9.53e-28	114
k141_103886_7	CARD|gb|ABD30512.1|ARO:3000839|arlS	24.4	279	466	451	6.61e-24	102
k141_103886_7	CARD|gb|CYF42523.1|ARO:3004047|kdpD	24.0	258	466	885	2.33e-11	65.1
k141_103886_8	CARD|gb|ATC67679.1|ARO:3000838|arlR	44.7	219	225	219	3.40e-60	187
k141_103886_8	CARD|gb|AAG06465.1|ARO:3005063|cprR	35.4	223	225	223	1.60e-45	150
k141_103886_8	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	38.4	224	225	232	6.49e-44	146
k141_103886_8	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.8	229	225	231	1.26e-43	145
k141_103886_8	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.5	223	225	231	7.07e-43	143
k141_103886_8	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.4	229	225	231	1.99e-42	142
k141_103886_8	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	35.1	228	225	230	3.86e-42	141
k141_103886_8	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.4	229	225	231	5.59e-42	141
k141_103886_8	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.2	229	225	231	1.11e-41	140
k141_103886_8	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.2	224	225	220	6.53e-41	138
k141_103886_27	SARG|gi|446048013|ref|WP_000125868.1|	36.7	229	247	648	4.26e-37	136
k141_103886_27	SARG|gb|AGN74946|ARO:3003749|salA	28.3	212	247	541	6.91e-13	66.6
k141_103886_27	SARG|gi|944535691|ref|WP_055747198.1|	22.4	219	247	492	1.20e-08	53.9
k141_103886_27	SARG|gi|1032346815|ref|WP_064200323.1|	21.9	219	247	492	1.61e-08	53.5
k141_103886_27	SARG|gi|496784101|ref|WP_009371362.1|	22.4	219	247	493	3.89e-08	52.4
k141_103886_27	SARG|gi|490350160|ref|WP_004229933.1|	23.4	197	247	493	5.22e-08	52.0
k141_103886_27	SARG|gi|651595894|ref|WP_026590859.1|	20.5	219	247	492	6.99e-08	51.6
k141_103886_27	SARG|gi|937111451|ref|WP_054550161.1|	21.5	219	247	493	9.39e-08	51.2
k141_103886_27	SARG|gi|860350489|ref|WP_048392759.1|	21.5	219	247	493	1.26e-07	50.8
k141_103886_27	SARG|gi|1033309939|gb|OAS18676.1|	21.5	219	247	492	3.03e-07	49.7
k141_26307_8	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	28.2	238	386	392	3.81e-24	101
k141_26307_8	CARD|gb|ABD30512.1|ARO:3000839|arlS	28.4	229	386	451	9.27e-21	92.4
k141_26307_8	CARD|gb|AEX49906.1|ARO:3003583|basS	25.6	234	386	477	7.53e-16	77.8
k141_98053_16	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	23.2	357	459	443	1.07e-11	65.5
k141_98053_34	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	38.7	697	641	703	1.58e-139	422
k141_98053_48	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	25.3	455	484	633	2.79e-27	114
k141_98053_48	SARG|gb|AQX82857.1|ARO:3004185|mecD	25.7	439	484	678	2.54e-22	99.4
k141_98053_48	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	26.0	431	484	674	7.98e-22	97.8
k141_98053_48	SARG|gb|BAI83385.1|ARO:3003440|mecB	26.0	431	484	674	2.52e-21	96.3
k141_98053_48	NCBI|WP_069996660.1|1|1|mecC3|mecC3|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC3|AMR|beta-lactam	24.0	433	484	665	1.04e-20	94.4
k141_98053_48	NCBI|WP_128268231.1|1|1|mecC2|mecC2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC2|AMR|beta-lactam	24.6	435	484	665	2.46e-20	93.2
k141_98053_48	megares|MEG_3799|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	22.8	434	484	664	1.36e-19	90.9
k141_98053_48	SARG|gb|CCC86795.1|ARO:3001209|mecC	23.7	435	484	665	7.55e-19	88.6
k141_98053_48	megares|MEG_3800|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	23.0	434	484	665	1.00e-18	88.2
k141_98053_48	ResF|penA_1_AF515059_1	23.5	405	484	581	9.28e-13	69.3
k141_115802_8	SARG|gi|686113687|ref|WP_031764317.1|	31.5	413	465	451	1.61e-64	214
k141_115802_8	SARG|gi|313609598|gb|EFR85124.1|	34.5	226	465	226	2.02e-43	151
k141_115802_8	SARG|HE999704.1.gene3064.p01	33.0	212	465	241	8.07e-30	115
k141_98163_17	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	21.4	487	495	504	4.86e-13	70.1
k141_98163_17	SARG|gb|WP_096809342.1|ARO:3007029|salE	26.5	185	495	543	2.14e-12	68.2
k141_98163_17	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	21.7	497	495	505	4.41e-11	63.9
k141_98163_17	SARG|gb|AAK76137.1|ARO:3000024|patA	23.6	229	495	564	4.83e-11	63.9
k141_98163_17	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	23.5	277	495	552	7.79e-10	60.1
k141_98163_17	SARG|gi|930482089|ref|WP_054228897.1|	24.1	232	495	599	1.09e-09	59.7
k141_98163_17	SARG|gi|985844137|ref|WP_060895163.1|	24.1	232	495	599	1.09e-09	59.7
k141_98163_17	SARG|gi|648667297|ref|WP_026359044.1|	22.1	240	495	605	5.81e-09	57.4
k141_98163_17	SARG|gi|926351744|ref|WP_053683383.1|	25.0	244	495	648	7.95e-09	57.0
k141_98163_17	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	23.3	219	495	550	1.27e-08	56.2
k141_98163_66	CARD|gb|AAC73788.1|ARO:3003841|kdpE	36.3	226	230	225	1.25e-43	145
k141_98163_66	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	35.8	226	230	225	4.98e-43	144
k141_98163_66	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	33.3	228	230	232	5.15e-38	131
k141_98163_66	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	33.3	228	230	232	5.15e-38	131
k141_98163_66	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	33.9	227	230	229	6.71e-38	130
k141_98163_66	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	33.5	227	230	231	1.10e-36	127
k141_98163_66	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.5	227	230	231	1.10e-36	127
k141_98163_66	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	34.2	222	230	223	1.26e-36	127
k141_98163_66	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.2	226	230	231	1.55e-36	127
k141_98163_66	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.6	226	230	231	3.07e-36	126
k141_98163_67	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	22.7	251	413	447	4.81e-12	66.2
k141_98163_68	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	42.7	232	232	255	3.34e-57	181
k141_98163_68	SARG|gi|851928815|ref|WP_048221086.1|	40.6	219	232	648	9.41e-50	171
k141_98163_68	SARG|gi|780033092|ref|WP_045444768.1|	40.6	219	232	648	9.41e-50	171
k141_98163_68	SARG|gb|AAV85982.1|ARO:3000535|macB	37.4	230	232	644	4.62e-49	169
k141_98163_68	SARG|gi|740856590|ref|WP_038641842.1|	40.6	219	232	648	4.83e-49	169
k141_98163_68	SARG|gi|922960663|ref|WP_053388845.1|	40.6	219	232	648	4.83e-49	169
k141_98163_68	SARG|gi|757799695|ref|WP_043016897.1|	40.6	219	232	648	6.69e-49	168
k141_98163_68	SARG|gi|1045891604|ref|WP_065554100.1|	40.6	219	232	648	6.69e-49	168
k141_98163_68	SARG|gi|507082903|ref|WP_016153652.1|	40.6	219	232	648	6.69e-49	168
k141_98163_68	SARG|gi|746243059|ref|WP_039291473.1|	41.1	219	232	648	6.69e-49	168
k141_122774_7	SARG|gb|AAV85982.1|ARO:3000535|macB	34.3	181	264	644	3.31e-21	91.7
k141_98246_20	SARG|gb|AML99881.1|ARO:3001327|mdtK	26.1	441	458	474	1.01e-45	164
k141_128417_7	SARG|gi|505177635|ref|WP_015364737.1|	28.4	437	455	451	1.11e-41	152
k141_128417_7	SARG|ZP_04679156	27.7	437	455	451	1.98e-39	146
k141_128417_7	SARG|gi|488374619|ref|WP_002444004.1|	26.1	437	455	452	9.57e-38	142
k141_128417_7	SARG|gi|1006223553|ref|WP_061745579.1|	26.4	450	455	451	8.88e-37	139
k141_128417_7	SARG|gi|446573690|ref|WP_000651036.1|	27.5	447	455	451	1.68e-36	138
k141_128417_7	SARG|gi|686432388|ref|WP_031921070.1|	27.3	447	455	451	1.68e-36	138
k141_128417_7	SARG|ZP_03986195	27.5	447	455	451	2.32e-36	138
k141_128417_7	SARG|gi|446573695|ref|WP_000651041.1|	27.5	447	455	451	2.32e-36	138
k141_128417_7	SARG|gi|446573707|ref|WP_000651053.1|	27.3	447	455	451	3.19e-36	137
k141_128417_7	SARG|gi|686448604|ref|WP_031928572.1|	27.1	447	455	451	3.19e-36	137
k141_128417_22	SARG|gi|446573707|ref|WP_000651053.1|	34.0	450	454	451	2.09e-66	218
k141_128417_34	SARG|gb|AAF63432|ARO:3003744|vatF	46.5	43	57	221	4.55e-08	45.8
k141_128417_34	SARG|U19459.gene.p01	42.9	49	57	212	2.20e-07	43.9
k141_128417_34	SARG|YP_002861121	56.3	32	57	212	5.80e-07	42.7
k141_128417_34	SARG|YP_001389621	56.3	32	57	212	5.80e-07	42.7
k141_128417_34	SARG|YP_001785579	56.3	32	57	212	8.01e-07	42.4
k141_128417_34	SARG|YP_001779894	56.3	32	57	212	1.11e-06	42.0
k141_62732_4	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.4	215	222	219	6.99e-51	163
k141_62732_4	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.4	215	222	219	1.40e-50	162
k141_62732_4	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.4	215	222	220	1.44e-50	162
k141_62732_4	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.4	215	222	220	2.04e-50	162
k141_62732_4	SARG|ZP_02848503	40.5	215	222	221	9.50e-49	158
k141_62732_4	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.0	215	222	220	2.09e-47	154
k141_62732_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	34.2	225	222	231	1.40e-38	132
k141_62732_4	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.7	226	222	232	4.45e-37	128
k141_62732_4	CARD|gb|AAD51348.1|ARO:3003066|smeR	35.6	222	222	229	3.23e-36	126
k141_62732_4	CARD|gb|ADM92605.1|ARO:3000553|adeR	28.4	225	222	247	1.10e-34	122
k141_62732_7	SARG|gi|723111645|ref|WP_033557217.1|	37.7	220	210	648	6.54e-31	117
k141_62732_7	SARG|gb|APB03219.1|ARO:3003986|TaeA	34.0	103	210	648	8.57e-07	47.8
k141_62732_7	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	30.9	81	210	568	8.86e-06	44.7
k141_62732_8	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	45.0	222	222	255	2.70e-64	199
k141_62732_8	SARG|gi|1033064422|ref|WP_064375412.1|	43.7	222	222	648	9.36e-54	181
k141_62732_8	SARG|gi|1001720867|ref|WP_061274204.1|	43.0	221	222	648	1.81e-53	180
k141_62732_8	SARG|YP_001438541	43.9	221	222	647	3.46e-53	179
k141_62732_8	SARG|gi|938461734|ref|WP_054625806.1|	43.9	221	222	647	3.46e-53	179
k141_62732_8	SARG|gi|938460528|ref|WP_054624864.1|	43.9	221	222	647	3.46e-53	179
k141_62732_8	SARG|gi|490522515|ref|WP_004387938.1|	43.9	221	222	647	3.46e-53	179
k141_62732_8	SARG|gi|1020141879|ref|WP_063264839.1|	44.1	220	222	647	4.81e-53	179
k141_62732_8	SARG|gi|742378414|ref|WP_038857601.1|	43.9	221	222	647	4.81e-53	179
k141_62732_8	SARG|gi|495736522|ref|WP_008461101.1|	42.5	221	222	648	9.40e-53	178
k141_62732_14	SARG|ZP_04679156	21.9	433	477	451	1.18e-35	136
k141_62732_14	SARG|gi|565830932|ref|WP_023914633.1|	22.4	434	477	451	1.08e-34	134
k141_62732_14	SARG|gi|686396521|ref|WP_031908504.1|	22.6	434	477	451	1.08e-34	134
k141_62732_14	SARG|gi|487138435|ref|WP_001629863.1|	22.6	434	477	451	2.04e-34	133
k141_62732_14	SARG|gi|446573707|ref|WP_000651053.1|	22.6	434	477	451	2.80e-34	132
k141_62732_14	SARG|gi|516415429|ref|WP_017804827.1|	22.1	434	477	451	3.83e-34	132
k141_62732_14	SARG|gi|686367913|ref|WP_031894914.1|	22.4	434	477	451	3.83e-34	132
k141_62732_14	SARG|gi|487135741|ref|WP_001627648.1|	22.4	434	477	451	3.83e-34	132
k141_62732_14	SARG|gi|486285962|ref|WP_001572033.1|	22.4	434	477	451	3.83e-34	132
k141_62732_14	SARG|gi|686320684|ref|WP_031875798.1|	22.4	434	477	451	3.83e-34	132
k141_62732_31	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	43.0	223	254	255	2.14e-61	192
k141_62732_31	SARG|gi|763399392|ref|WP_044256358.1|	38.0	221	254	648	1.36e-47	166
k141_62732_31	SARG|gi|391288090|gb|EIQ46599.1|	38.9	221	254	645	2.52e-47	165
k141_62732_31	SARG|Q83LR7	38.9	221	254	648	2.60e-47	165
k141_62732_31	SARG|gi|647325472|ref|WP_025760953.1|	38.9	221	254	648	2.60e-47	165
k141_62732_31	SARG|gi|647323678|ref|WP_025760497.1|	38.9	221	254	648	2.60e-47	165
k141_62732_31	SARG|gi|754964360|ref|WP_042320280.1|	38.0	221	254	648	2.60e-47	165
k141_62732_31	SARG|gi|736472622|ref|WP_034494292.1|	37.3	233	254	648	2.60e-47	165
k141_62732_31	SARG|gi|693054987|ref|WP_032223114.1|	38.5	221	254	648	3.59e-47	164
k141_62732_31	SARG|gi|545167026|ref|WP_021521592.1|	38.5	221	254	648	4.97e-47	164
k141_68822_6	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	38.7	142	376	373	1.33e-21	94.0
k141_92955_5	SARG|gi|446048013|ref|WP_000125868.1|	28.9	204	214	648	6.53e-16	74.7
k141_92955_5	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.0	189	214	664	9.53e-13	65.5
k141_92955_6	SARG|gi|510143239|gb|AGN36970.1|	30.5	239	271	313	5.40e-17	78.2
k141_92955_6	SARG|gi|445996719|ref|WP_000074574.1|	31.1	241	271	309	9.74e-17	77.4
k141_92955_6	SARG|P42332	31.9	210	271	306	1.77e-16	76.6
k141_92955_6	SARG|ABB80128	31.9	210	271	306	1.77e-16	76.6
k141_92955_6	SARG|gi|447195835|ref|WP_001273091.1|	31.3	227	271	306	1.77e-16	76.6
k141_92955_6	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	31.9	210	271	306	1.77e-16	76.6
k141_92955_6	SARG|gi|447195836|ref|WP_001273092.1|	31.3	227	271	306	1.77e-16	76.6
k141_92955_6	SARG|gi|507044560|ref|WP_016115614.1|	31.8	211	271	306	3.31e-16	75.9
k141_92955_6	SARG|gi|445996722|ref|WP_000074577.1|	31.1	241	271	309	3.41e-16	75.9
k141_92955_6	SARG|ZP_04081918	31.3	227	271	306	4.53e-16	75.5
k141_92955_9	SARG|DQ018711.1.gene4.p01	34.0	262	329	322	4.81e-34	126
k141_92955_9	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	36.2	232	329	323	9.54e-34	125
k141_92955_9	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	31.0	274	329	314	3.00e-33	124
k141_92955_9	SARG|gi|737310392|ref|WP_035293250.1|	33.2	262	329	323	6.97e-33	123
k141_92955_9	SARG|YP_002333394	38.1	236	329	323	9.71e-33	122
k141_92955_9	SARG|gi|498515089|ref|WP_010815296.1|	37.3	236	329	323	2.62e-32	121
k141_92955_9	SARG|gi|985522333|ref|WP_060811962.1|	37.3	236	329	323	2.62e-32	121
k141_92955_9	SARG|AF310956.2.gene5.p01	37.7	236	329	323	3.64e-32	121
k141_92955_9	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	37.7	236	329	323	3.64e-32	121
k141_92955_9	SARG|gi|740152780|ref|WP_037997109.1|	33.8	237	329	322	3.60e-31	118
k141_128879_3	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	28.0	325	511	447	3.47e-25	107
k141_128879_3	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.7	325	511	447	2.80e-24	104
k141_128879_3	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.7	325	511	447	2.80e-24	104
k141_128879_3	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.7	325	511	447	2.80e-24	104
k141_128879_3	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.1	325	511	454	1.39e-22	99.4
k141_128879_3	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	24.2	223	511	392	2.62e-22	97.8
k141_128879_3	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	25.3	249	511	364	4.69e-22	96.7
k141_128879_3	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	25.3	249	511	364	4.69e-22	96.7
k141_128879_3	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.6	293	511	361	1.99e-17	82.8
k141_128879_3	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	23.2	203	511	359	6.59e-16	78.2
k141_75173_14	CARD|gb|BAB36671.1|ARO:3000832|evgA	22.2	207	218	204	2.83e-13	65.1
k141_75173_14	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	27.7	112	218	228	6.43e-11	58.9
k141_75173_14	CARD|gb|ADM92605.1|ARO:3000553|adeR	22.2	216	218	247	1.71e-07	49.3
k141_75173_14	CARD|gb|AAD51348.1|ARO:3003066|smeR	26.1	115	218	229	1.75e-06	46.2
k141_75173_14	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.8	84	218	232	1.78e-06	46.2
k141_75173_14	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.8	84	218	232	3.25e-06	45.4
k141_75173_14	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.8	84	218	232	3.25e-06	45.4
k141_75173_14	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.8	84	218	232	3.25e-06	45.4
k141_75173_14	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.8	84	218	232	3.25e-06	45.4
k141_75173_14	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.8	84	218	232	5.94e-06	44.7
k141_75173_16	SARG|gi|445996710|ref|WP_000074565.1|	31.6	225	510	309	1.97e-13	70.1
k141_75173_16	SARG|gi|542061059|gb|ERI11611.1|	31.8	211	510	316	3.78e-13	69.3
k141_75173_16	SARG|gi|445996719|ref|WP_000074574.1|	31.1	209	510	309	8.54e-13	68.2
k141_75173_16	SARG|gi|447195835|ref|WP_001273091.1|	32.5	209	510	306	1.11e-12	67.8
k141_75173_16	SARG|gi|447195836|ref|WP_001273092.1|	32.5	209	510	306	1.11e-12	67.8
k141_75173_16	SARG|gi|895736250|emb|COF64653.1|	31.1	225	510	309	1.54e-12	67.4
k141_75173_16	SARG|gi|446110087|ref|WP_000187942.1|	31.1	225	510	309	1.54e-12	67.4
k141_75173_16	SARG|gi|445996714|ref|WP_000074569.1|	31.3	224	510	309	2.06e-12	67.0
k141_75173_16	SARG|gi|814314593|emb|CKF49145.1|	31.0	210	510	309	2.06e-12	67.0
k141_75173_16	SARG|gi|895808656|emb|COR83787.1|	29.1	223	510	309	2.06e-12	67.0
k141_75173_20	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	29.6	260	382	392	5.87e-29	115
k141_75173_20	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	31.3	243	382	370	3.41e-26	107
k141_75173_20	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	29.6	243	382	380	1.23e-24	102
k141_75173_20	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.6	243	382	380	1.23e-24	102
k141_75173_20	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	32.9	228	382	381	1.71e-24	102
k141_75173_20	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	32.9	228	382	381	1.71e-24	102
k141_75173_20	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.5	249	382	352	4.15e-24	100
k141_75173_20	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.8	224	382	367	5.03e-24	100
k141_75173_20	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.8	224	382	368	5.10e-24	100
k141_75173_20	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.5	249	382	376	5.61e-24	100
k141_75173_21	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	45.1	226	234	231	9.10e-63	194
k141_75173_21	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	42.6	237	234	235	1.66e-61	191
k141_75173_21	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	46.5	226	234	232	1.58e-58	184
k141_75173_21	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.5	232	234	231	2.18e-58	183
k141_75173_21	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.1	232	234	231	8.73e-58	182
k141_75173_21	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.1	232	234	231	1.75e-57	181
k141_75173_21	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	42.9	233	234	232	1.80e-57	181
k141_75173_21	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	42.5	233	234	232	5.11e-57	180
k141_75173_21	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.1	233	234	231	1.41e-56	179
k141_75173_21	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.3	234	234	232	2.05e-56	178
k141_51057_16	CARD|gb|BAA15221.2|ARO:3000263|marA	28.7	94	298	127	2.29e-08	50.8
k141_93266_6	SARG|L42544.gene.p01	47.7	128	611	651	8.69e-29	120
k141_93266_6	SARG|AAV80410	47.7	128	611	651	8.69e-29	120
k141_93266_6	SARG|AJ514254.gene.p01	46.9	128	611	640	3.50e-27	115
k141_93266_6	SARG|Q02652	47.4	133	611	639	1.43e-25	110
k141_93266_6	SARG|ABB70054	43.8	128	611	639	3.17e-23	103
k141_93266_6	SARG|ABI81214	43.8	128	611	639	3.17e-23	103
k141_93266_6	SARG|BAB71968	43.8	128	611	639	3.17e-23	103
k141_93266_6	SARG|YP_002738300	43.8	128	611	639	3.17e-23	103
k141_93266_6	SARG|X04388.gene.p01	43.0	128	611	639	4.21e-23	102
k141_93266_6	SARG|gi|291587251|gb|ADE19326.1|	40.1	137	611	644	4.27e-23	102
k141_93266_13	SARG|gi|488120365|ref|WP_002191762.1|	28.7	244	499	309	6.39e-12	65.5
k141_93266_13	SARG|gi|447057509|ref|WP_001134765.1|	28.4	243	499	309	6.39e-12	65.5
k141_93266_13	SARG|gi|542061059|gb|ERI11611.1|	30.4	237	499	316	6.77e-12	65.5
k141_93266_13	SARG|gi|445996719|ref|WP_000074574.1|	28.5	235	499	309	8.56e-12	65.1
k141_93266_13	SARG|gi|445996722|ref|WP_000074577.1|	28.5	235	499	309	1.15e-11	64.7
k141_93266_13	SARG|gi|507055561|ref|WP_016126482.1|	28.0	243	499	309	1.53e-11	64.3
k141_93266_13	SARG|gi|507023808|ref|WP_016095885.1|	28.4	243	499	309	1.53e-11	64.3
k141_93266_13	SARG|gi|445996723|ref|WP_000074578.1|	28.5	235	499	309	1.53e-11	64.3
k141_93266_13	SARG|gb|AAK76137.1|ARO:3000024|patA	22.6	230	499	564	1.60e-11	65.5
k141_93266_13	SARG|gi|884875933|emb|CKG93789.1|	28.1	235	499	309	2.05e-11	63.9
k141_93266_17	SARG|gi|1035706844|ref|WP_064548272.1|	30.4	224	246	648	1.28e-18	83.6
k141_93266_17	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	27.4	208	246	505	1.61e-12	65.5
k141_93266_17	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	30.3	201	246	504	3.19e-11	61.6
k141_93266_17	SARG|gb|AVI44920.1|ARO:3004470|poxtA	26.1	218	246	542	7.46e-07	48.5
k141_93266_17	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	26.1	218	246	544	7.46e-07	48.5
k141_75562_3	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	55.9	34	354	346	5.72e-06	46.6
k141_75562_12	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	41.5	229	239	255	3.30e-59	186
k141_75562_12	SARG|gi|1035670474|ref|WP_064517458.1|	43.6	236	239	648	2.28e-56	189
k141_75562_12	SARG|gi|736472622|ref|WP_034494292.1|	43.6	236	239	648	3.17e-56	188
k141_75562_12	SARG|gi|1035717981|ref|WP_064557480.1|	43.6	236	239	648	6.15e-56	187
k141_75562_12	SARG|Q83LR7	45.9	222	239	648	8.56e-56	187
k141_75562_12	SARG|gi|647325472|ref|WP_025760953.1|	45.9	222	239	648	8.56e-56	187
k141_75562_12	SARG|gi|647323678|ref|WP_025760497.1|	45.9	222	239	648	8.56e-56	187
k141_75562_12	SARG|gi|1035686596|ref|WP_064530178.1|	45.5	222	239	648	2.31e-55	186
k141_75562_12	SARG|gi|446110305|ref|WP_000188160.1|	45.5	222	239	648	3.21e-55	186
k141_75562_12	SARG|gi|896106549|ref|WP_049136608.1|	43.5	237	239	646	1.17e-54	184
k141_75562_14	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	34.2	225	225	223	6.23e-39	133
k141_75562_14	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	37.2	223	225	225	5.18e-38	130
k141_75562_14	CARD|gb|AAC73788.1|ARO:3003841|kdpE	37.2	223	225	225	5.18e-38	130
k141_75562_14	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	31.2	234	225	233	1.57e-31	114
k141_75562_14	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	30.4	237	225	235	9.00e-31	112
k141_75562_14	CARD|gb|AAG05188.1|ARO:3005068|ParR	32.0	225	225	235	9.72e-30	109
k141_75562_14	CARD|gb|AAD51348.1|ARO:3003066|smeR	32.0	228	225	229	4.62e-29	107
k141_75562_14	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.5	233	225	231	9.55e-29	107
k141_75562_14	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	30.5	239	225	239	1.61e-28	106
k141_75562_14	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	29.9	224	225	228	6.82e-28	104
k141_22260_3	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	24.9	305	462	392	6.21e-22	96.3
k141_22260_3	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	25.8	337	462	382	1.38e-21	95.1
k141_22260_3	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	25.8	337	462	382	1.38e-21	95.1
k141_22260_3	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	28.3	269	462	386	2.63e-21	94.4
k141_22260_3	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.3	269	462	386	2.63e-21	94.4
k141_22260_3	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.3	251	462	386	3.55e-21	94.0
k141_22260_3	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	28.3	251	462	386	3.55e-21	94.0
k141_22260_3	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	28.3	269	462	388	6.59e-21	93.2
k141_22260_3	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.3	269	462	388	6.59e-21	93.2
k141_22260_3	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	28.3	251	462	384	1.15e-20	92.4
k141_22260_4	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	39.9	233	246	233	5.85e-51	165
k141_22260_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.6	233	246	232	8.03e-51	164
k141_22260_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.6	233	246	232	8.03e-51	164
k141_22260_4	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	39.4	236	246	229	1.86e-48	158
k141_22260_4	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	38.5	231	246	230	7.63e-48	157
k141_22260_4	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	40.7	226	246	231	6.24e-47	154
k141_22260_4	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.0	230	246	231	1.24e-46	154
k141_22260_4	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	39.2	232	246	239	1.56e-46	154
k141_22260_4	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.0	230	246	231	1.76e-46	153
k141_22260_4	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.0	230	246	231	2.48e-46	153
k141_22260_5	SARG|gi|507044560|ref|WP_016115614.1|	54.7	223	244	306	2.89e-76	232
k141_22260_5	SARG|gi|446026113|ref|WP_000103968.1|	54.3	223	244	306	2.32e-75	229
k141_22260_5	SARG|gi|447057509|ref|WP_001134765.1|	54.1	220	244	309	2.90e-74	227
k141_22260_5	SARG|YP_001373621	53.6	222	244	318	3.80e-74	227
k141_22260_5	SARG|P42332	55.2	212	244	306	7.52e-74	226
k141_22260_5	SARG|ABB80128	55.2	212	244	306	1.06e-73	225
k141_22260_5	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	55.5	209	244	306	2.13e-73	224
k141_22260_5	SARG|gi|510143239|gb|AGN36970.1|	55.5	209	244	313	2.63e-73	224
k141_22260_5	SARG|gi|500194536|ref|WP_011867743.1|	52.0	225	244	306	3.02e-73	224
k141_22260_5	SARG|AAD21213	54.7	212	244	306	6.05e-73	223
k141_22260_36	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.5	229	230	232	8.14e-55	174
k141_22260_36	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.1	219	230	220	9.14e-54	171
k141_22260_36	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.1	219	230	219	1.25e-53	171
k141_22260_36	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.1	219	230	220	1.29e-53	171
k141_22260_36	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.6	219	230	220	5.18e-53	169
k141_22260_36	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.6	219	230	219	1.01e-52	168
k141_22260_36	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	38.8	227	230	230	1.97e-52	168
k141_22260_36	SARG|ZP_02848503	40.7	221	230	221	2.14e-52	167
k141_22260_36	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.7	230	230	232	1.18e-51	166
k141_22260_36	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.8	228	230	232	3.35e-51	165
k141_135017_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	25.2	286	362	370	9.24e-19	85.5
k141_135017_1	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	26.6	252	362	380	8.30e-18	82.8
k141_135017_1	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.6	252	362	380	8.30e-18	82.8
k141_135017_1	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	24.7	279	362	357	2.33e-17	81.3
k141_135017_1	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	24.7	279	362	357	2.33e-17	81.3
k141_135017_1	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.8	260	362	381	2.78e-17	81.3
k141_135017_1	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.8	260	362	381	2.78e-17	81.3
k141_135017_1	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.6	258	362	381	5.07e-17	80.5
k141_135017_1	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.6	258	362	381	5.07e-17	80.5
k141_135017_1	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.4	260	362	381	1.68e-16	79.0
k141_135017_5	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.2	120	557	219	1.05e-09	57.8
k141_135017_6	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	39.9	516	502	533	6.42e-99	307
k141_135017_6	SARG|AF353562.gene.p01	36.8	361	502	369	2.31e-54	186
k141_135017_16	SARG|gi|446048013|ref|WP_000125868.1|	24.3	243	506	648	1.84e-16	81.3
k141_135017_16	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.8	212	506	664	1.79e-15	78.2
k141_135017_16	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	24.5	245	506	343	1.12e-11	65.1
k141_135017_16	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	21.5	205	506	293	6.35e-08	53.1
k141_135017_16	SARG|gb|AAK76137.1|ARO:3000024|patA	21.8	211	506	564	4.97e-07	51.2
k141_135022_3	SARG|gi|403023847|gb|EJY36064.1|	40.1	202	338	200	1.04e-41	143
k141_135022_3	SARG|gi|452996213|gb|AGG19398.1|	42.1	183	338	268	2.40e-41	144
k141_135022_3	SARG|gi|498515090|ref|WP_010815297.1|	42.1	183	338	268	2.40e-41	144
k141_135022_3	SARG|gi|452996227|gb|AGG19410.1|	40.1	202	338	252	4.38e-41	143
k141_135022_3	SARG|gi|488259314|ref|WP_002330522.1|	40.1	202	338	268	6.64e-41	143
k141_135022_3	SARG|gi|1036536100|emb|SAM71699.1|	40.1	202	338	268	6.64e-41	143
k141_135022_3	SARG|gi|403219412|emb|CCJ27774.1|	40.1	202	338	268	6.64e-41	143
k141_135022_3	SARG|KF823969.1.gene3.p01	40.1	202	338	268	6.64e-41	143
k141_135022_3	SARG|Q47746	41.5	183	338	268	9.31e-41	142
k141_135022_3	SARG|FJ349556.1.gene4.p01	38.4	198	338	233	6.48e-31	115
k141_135022_23	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	27.2	228	388	337	2.42e-14	72.4
k141_135022_23	SARG|KF478993.1.gene2.p01	26.4	261	388	350	9.00e-13	67.8
k141_135022_24	SARG|gb|AEA37904.1|ARO:3003112|lsaC	22.8	535	574	492	2.16e-14	74.7
k141_135022_24	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	28.9	242	574	504	2.12e-13	71.6
k141_135022_24	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	23.3	416	574	550	3.10e-13	71.2
k141_135022_24	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	28.9	239	574	505	6.55e-13	70.1
k141_135022_24	SARG|gi|488247627|ref|WP_002318835.1|	26.4	208	574	492	3.20e-07	52.0
k141_135022_24	SARG|gi|488231473|ref|WP_002302681.1|	26.4	208	574	492	5.59e-07	51.2
k141_135022_24	SARG|gi|488216250|ref|WP_002287458.1|	26.4	208	574	492	5.59e-07	51.2
k141_135022_24	SARG|DQ823382.1.gene1.p01	25.3	253	574	522	5.79e-07	51.2
k141_135022_24	megares|MEG_7687|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	25.3	253	574	522	5.79e-07	51.2
k141_135022_24	megares|MEG_7686|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	25.3	253	574	522	5.79e-07	51.2
k141_135022_37	megares|MEG_3786|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	28.0	214	441	585	3.54e-18	85.9
k141_135022_37	NCBI|WP_000952923.1|1|1|mecR1|mecR1|regulation|2|METHICILLIN|beta-lactam|beta-lactam_sensor/signal_transducer_MecR1|AMR|beta-lactam	28.0	214	441	585	3.54e-18	85.9
k141_135022_39	NCBI|WP_001284656.1|1|1|blaI_of_Z|blaI_of_Z|regulation|2|beta-lactam|beta-lactam|penicillinase_repressor_BlaI|AMR|beta-lactam	28.0	100	110	126	7.60e-08	46.2
k141_5359_11	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.5	110	259	219	4.49e-12	62.8
k141_5359_11	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.0	100	259	228	9.83e-10	56.2
k141_5359_39	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.6	224	230	231	1.28e-61	191
k141_5359_39	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	44.0	225	230	233	4.40e-60	187
k141_5359_39	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.7	230	230	232	8.56e-60	187
k141_5359_39	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.7	230	230	232	8.56e-60	187
k141_5359_39	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.4	228	230	231	1.34e-58	184
k141_5359_39	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.4	228	230	231	1.34e-58	184
k141_5359_39	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	44.0	225	230	232	2.77e-58	183
k141_5359_39	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.1	227	230	231	5.38e-58	182
k141_5359_39	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	42.5	228	230	235	8.58e-58	182
k141_5359_39	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.6	227	230	231	1.52e-57	181
k141_5359_40	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.1	280	408	370	1.41e-26	108
k141_5359_40	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	29.2	236	408	359	3.83e-25	104
k141_5359_40	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	25.7	280	408	365	5.04e-24	101
k141_5359_40	CARD|gb|AEX49906.1|ARO:3003583|basS	29.5	227	408	477	1.55e-22	98.2
k141_5359_40	SARG|gb|AAG05187.1|ARO:3005067|ParS	24.6	224	408	428	6.88e-22	95.9
k141_5359_40	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	28.9	225	408	364	4.39e-21	92.8
k141_5359_40	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	28.9	225	408	364	4.39e-21	92.8
k141_5359_57	NCBI|WP_231869585.1|1|1|npmB2|npmB||2|aminoglycoside|aminoglycoside|16S_rRNA_(adenine(1408)-N(1))-methyltransferase_NpmB2|AMR|aminoglycoside	30.4	125	215	217	3.89e-06	45.1
k141_5359_57	NCBI|WP_231869586.1|1|1|npmB1|npmB||2|aminoglycoside|aminoglycoside|16S_rRNA_(adenine(1408)-N(1))-methyltransferase_NpmB1|AMR|aminoglycoside	31.4	118	215	217	7.13e-06	44.3
k141_5359_58	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.9	254	496	356	1.74e-29	117
k141_5359_58	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.5	255	496	346	3.76e-29	116
k141_5359_58	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.2	255	496	356	6.09e-29	116
k141_5359_58	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.2	255	496	355	2.85e-28	114
k141_5359_58	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	30.2	255	496	355	2.85e-28	114
k141_5359_58	SARG|ACM47285	30.2	255	496	363	3.25e-28	114
k141_5359_58	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.2	255	496	356	5.41e-28	113
k141_5359_58	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	28.8	288	496	355	2.52e-27	111
k141_5359_58	SARG|BAE96115	28.8	288	496	355	2.52e-27	111
k141_5359_58	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	26.6	199	496	209	3.69e-16	76.3
k141_5615_5	SARG|gb|AAB05626.1|ARO:3002943|vanHB	33.0	276	321	323	5.98e-30	115
k141_5615_5	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	31.7	281	321	323	8.31e-30	114
k141_5615_5	SARG|Q47748	33.0	276	321	323	1.15e-29	114
k141_5615_5	SARG|gi|985522333|ref|WP_060811962.1|	33.0	276	321	323	1.60e-29	114
k141_5615_5	SARG|YP_002333394	31.9	276	321	323	2.22e-29	113
k141_5615_5	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	31.9	276	321	323	2.22e-29	113
k141_5615_5	SARG|gi|498515089|ref|WP_010815296.1|	32.6	276	321	323	3.09e-29	113
k141_5615_5	SARG|AF310956.2.gene5.p01	31.5	276	321	323	8.26e-29	112
k141_5615_5	SARG|KF478993.1.gene2.p01	28.7	279	321	350	9.37e-29	112
k141_5615_5	SARG|AY082011.1.gene6.p01	31.9	276	321	323	1.15e-28	111
k141_106571_9	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.1	214	218	219	1.27e-44	147
k141_106571_9	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.1	214	218	220	1.31e-44	147
k141_106571_9	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.1	214	218	220	1.85e-44	147
k141_106571_9	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.7	214	218	219	1.01e-43	145
k141_106571_9	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.0	223	218	232	1.03e-43	145
k141_106571_9	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.7	214	218	220	2.94e-43	144
k141_106571_9	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.0	223	218	231	3.99e-43	144
k141_106571_9	SARG|ZP_02848503	40.6	217	218	221	4.25e-40	135
k141_106571_9	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	36.7	229	218	230	8.51e-39	132
k141_106571_9	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.2	221	218	228	2.26e-38	131
k141_106571_10	SARG|gb|AAG05187.1|ARO:3005067|ParS	27.8	277	472	428	2.09e-22	98.2
k141_106571_37	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.1	534	642	655	8.14e-111	346
k141_106571_37	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.0	534	642	655	1.74e-109	343
k141_106571_37	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.0	534	642	655	1.74e-109	343
k141_106571_37	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.0	534	642	655	2.45e-109	342
k141_106571_37	SARG|gb|AKA86814|ARO:3003746|optrA	36.0	534	642	655	2.45e-109	342
k141_106571_37	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.8	534	642	655	1.34e-108	340
k141_106571_37	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.8	534	642	655	1.89e-108	340
k141_106571_37	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.8	534	642	655	1.89e-108	340
k141_106571_37	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.8	534	642	655	1.89e-108	340
k141_106571_37	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.8	534	642	655	1.89e-108	340
k141_106571_44	SARG|gb|ABA71733.1|ARO:3002972|vanTG	35.9	382	387	712	1.35e-71	236
k141_106571_44	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	34.5	383	387	711	1.51e-60	206
k141_106571_44	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	33.0	382	387	712	7.48e-57	196
k141_106571_44	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	30.5	364	387	366	5.49e-54	181
k141_106571_44	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	33.8	382	387	700	1.57e-53	187
k141_106571_44	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	33.8	379	387	700	3.98e-52	183
k141_106571_44	SARG|AAY67970	32.4	376	387	698	7.42e-52	182
k141_106571_44	SARG|gi|498467693|ref|WP_010773049.1|	29.8	373	387	700	8.89e-49	174
k141_106571_44	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	34.1	337	387	700	8.89e-49	174
k141_106571_44	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	32.2	379	387	706	3.37e-48	172
k141_106571_51	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	33.3	300	290	293	3.23e-42	145
k141_106571_54	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	59.6	52	66	416	1.33e-18	76.3
k141_28508_14	SARG|gb|AAV85982.1|ARO:3000535|macB	25.4	469	452	644	5.53e-23	100
k141_28508_14	SARG|gi|693066875|ref|WP_032232318.1|	23.9	460	452	648	4.30e-21	95.1
k141_28508_14	SARG|gi|487410704|ref|WP_001678420.1|	23.9	460	452	648	4.30e-21	95.1
k141_28508_14	SARG|gi|487310756|ref|WP_001632756.1|	23.7	460	452	648	5.74e-21	94.7
k141_28508_14	SARG|gi|736472622|ref|WP_034494292.1|	23.5	460	452	648	5.74e-21	94.7
k141_28508_14	SARG|gi|671541568|ref|WP_031525212.1|	24.0	462	452	648	5.74e-21	94.7
k141_28508_14	SARG|gi|487612007|ref|WP_001735062.1|	23.7	460	452	648	1.02e-20	94.0
k141_28508_14	SARG|gi|487600024|ref|WP_001730664.1|	23.7	460	452	648	1.02e-20	94.0
k141_28508_14	SARG|gi|1035670474|ref|WP_064517458.1|	23.7	460	452	648	1.36e-20	93.6
k141_28508_14	SARG|gi|485866062|ref|WP_001464282.1|	23.7	460	452	648	1.36e-20	93.6
k141_28508_16	SARG|gi|803568669|ref|WP_046077412.1|	45.0	222	261	648	5.85e-62	204
k141_28508_16	SARG|gi|446110352|ref|WP_000188207.1|	45.0	222	261	648	5.85e-62	204
k141_28508_16	SARG|YP_002382193	45.0	222	261	648	5.85e-62	204
k141_28508_16	SARG|gi|803575554|ref|WP_046081557.1|	45.0	222	261	648	5.85e-62	204
k141_28508_16	SARG|gi|446110351|ref|WP_000188206.1|	45.0	222	261	648	5.85e-62	204
k141_28508_16	SARG|gi|446110305|ref|WP_000188160.1|	45.2	221	261	648	8.87e-59	196
k141_28508_16	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	41.2	221	261	255	9.84e-59	186
k141_28508_16	SARG|gi|585349466|ref|WP_024231081.1|	45.2	221	261	648	1.24e-58	196
k141_28508_16	SARG|gi|585345156|ref|WP_024226778.1|	45.2	221	261	648	1.24e-58	196
k141_28508_16	SARG|gi|494938585|ref|WP_007664615.1|	44.8	221	261	647	2.37e-58	195
k141_28508_18	SARG|ZP_04081918	28.4	303	303	306	7.33e-33	122
k141_28508_18	SARG|YP_001373621	32.6	218	303	318	4.92e-32	120
k141_28508_18	SARG|gi|447195835|ref|WP_001273091.1|	32.1	218	303	306	5.41e-32	119
k141_28508_18	SARG|gi|447195836|ref|WP_001273092.1|	32.1	218	303	306	5.41e-32	119
k141_28508_18	SARG|P42332	31.7	218	303	306	1.05e-31	119
k141_28508_18	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	31.7	218	303	306	1.05e-31	119
k141_28508_18	SARG|gi|510143239|gb|AGN36970.1|	31.7	218	303	313	1.21e-31	119
k141_28508_18	SARG|ABB80128	31.7	218	303	306	2.05e-31	118
k141_28508_18	SARG|gi|500194536|ref|WP_011867743.1|	32.5	209	303	306	5.55e-31	117
k141_28508_18	SARG|AAD21213	31.2	218	303	306	7.73e-31	116
k141_28508_21	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	29.6	284	299	293	4.15e-26	103
k141_28508_21	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	26.9	219	299	307	2.52e-18	82.4
k141_28508_21	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	28.4	204	299	343	4.97e-18	82.0
k141_28508_21	SARG|gi|542061059|gb|ERI11611.1|	27.4	201	299	316	7.14e-18	81.3
k141_28508_21	SARG|gi|500194536|ref|WP_011867743.1|	28.0	193	299	306	2.24e-17	79.7
k141_28508_21	SARG|gb|AAA26793|ARO:3003748|oleC	28.3	219	299	325	2.05e-15	74.3
k141_28508_21	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	28.6	217	299	325	2.79e-15	73.9
k141_28508_21	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.7	202	299	655	5.57e-11	62.0
k141_28508_21	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.7	202	299	655	5.57e-11	62.0
k141_28508_21	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.7	202	299	655	5.57e-11	62.0
k141_28508_37	SARG|gb|AAK76136.1|ARO:3000025|patB	33.5	585	599	588	2.71e-100	315
k141_28508_37	SARG|gb|AYV52072.1|ARO:3002882|lmrD	34.7	524	599	664	3.75e-94	301
k141_28508_37	SARG|gb|CDO61516.1|ARO:3003949|efrB	43.6	335	599	362	2.23e-86	272
k141_28508_37	SARG|gi|928900436|ref|WP_053931243.1|	30.7	587	599	600	1.90e-78	258
k141_28508_37	SARG|gi|664579989|ref|WP_031094015.1|	30.7	587	599	601	1.94e-78	258
k141_28508_37	SARG|gi|516795764|ref|WP_018105258.1|	30.4	586	599	601	5.30e-78	257
k141_28508_37	SARG|gi|944009777|ref|WP_055601444.1|	30.1	591	599	628	9.69e-78	257
k141_28508_37	SARG|gi|497748188|ref|WP_010062372.1|	29.8	587	599	605	1.13e-77	256
k141_28508_37	SARG|gi|1045390184|ref|WP_065479071.1|	30.0	587	599	605	1.13e-77	256
k141_28508_37	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	31.4	596	599	579	1.22e-77	256
k141_28508_38	SARG|gb|WP_104671188.1|ARO:3003948|efrA	37.2	584	612	575	3.08e-121	370
k141_28508_38	SARG|gb|AAK76137.1|ARO:3000024|patA	32.4	601	612	564	9.67e-93	295
k141_28508_38	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	27.7	617	612	579	2.11e-61	213
k141_28508_38	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	26.7	617	612	579	1.06e-59	208
k141_28508_38	SARG|gi|1011969930|ref|WP_062776015.1|	25.8	604	612	601	3.62e-55	196
k141_28508_38	SARG|gi|926351744|ref|WP_053683383.1|	26.2	572	612	648	2.71e-54	194
k141_28508_38	SARG|gi|943909899|ref|WP_055545300.1|	25.7	595	612	601	8.98e-54	192
k141_28508_38	SARG|gi|860594225|ref|WP_048475168.1|	25.7	607	612	620	1.21e-53	192
k141_28508_38	SARG|gi|917166849|ref|WP_051773561.1|	26.2	564	612	620	3.16e-53	191
k141_28508_38	SARG|gi|944470764|ref|WP_055701183.1|	26.6	598	612	601	3.24e-53	191
k141_28508_56	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	36.0	222	226	223	5.85e-43	143
k141_28508_56	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.2	230	226	232	4.69e-41	139
k141_28508_56	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	34.8	230	226	232	1.32e-40	137
k141_28508_56	CARD|gb|AAD51348.1|ARO:3003066|smeR	36.2	221	226	229	7.55e-39	133
k141_28508_56	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.9	230	226	231	2.47e-37	129
k141_28508_56	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.5	230	226	231	9.74e-37	127
k141_28508_56	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	33.5	227	226	231	1.37e-36	127
k141_28508_56	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.5	230	226	231	3.84e-36	126
k141_28508_56	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.5	228	226	231	5.41e-36	125
k141_28508_56	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.2	223	226	232	1.55e-35	124
k141_28508_63	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	50.4	254	256	255	1.70e-89	264
k141_28508_63	SARG|YP_001438541	39.2	222	256	647	7.04e-46	161
k141_28508_63	SARG|gi|938461734|ref|WP_054625806.1|	39.2	222	256	647	7.04e-46	161
k141_28508_63	SARG|gi|938460528|ref|WP_054624864.1|	39.2	222	256	647	7.04e-46	161
k141_28508_63	SARG|gi|490522515|ref|WP_004387938.1|	39.2	222	256	647	7.04e-46	161
k141_28508_63	SARG|gi|1020141879|ref|WP_063264839.1|	39.2	222	256	647	9.73e-46	160
k141_28508_63	SARG|gi|754724054|ref|WP_042095806.1|	37.9	224	256	648	9.82e-46	160
k141_28508_63	SARG|gi|555268037|ref|WP_023249477.1|	36.3	234	256	648	9.82e-46	160
k141_28508_63	SARG|gi|693238509|ref|WP_032348033.1|	37.9	224	256	648	9.82e-46	160
k141_28508_63	SARG|gi|485870849|ref|WP_001467831.1|	37.9	224	256	648	9.82e-46	160
k141_28508_76	SARG|gi|446048013|ref|WP_000125868.1|	28.2	248	496	648	3.41e-19	89.7
k141_28508_76	SARG|gi|542061059|gb|ERI11611.1|	27.1	229	496	316	4.38e-15	75.1
k141_28508_76	SARG|gi|447195835|ref|WP_001273091.1|	27.1	203	496	306	1.73e-14	73.2
k141_28508_76	SARG|gi|447195836|ref|WP_001273092.1|	27.1	203	496	306	1.73e-14	73.2
k141_28508_76	SARG|ZP_04081918	27.1	210	496	306	2.32e-14	72.8
k141_28508_76	SARG|gb|AYV52072.1|ARO:3002882|lmrD	25.6	211	496	664	4.96e-14	73.6
k141_28508_76	SARG|gi|507055561|ref|WP_016126482.1|	28.0	207	496	309	5.79e-14	71.6
k141_28508_76	SARG|P42332	24.9	249	496	306	7.55e-14	71.2
k141_28508_76	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	24.9	249	496	306	7.55e-14	71.2
k141_28508_76	SARG|gi|510143239|gb|AGN36970.1|	24.9	249	496	313	8.08e-14	71.2
k141_28508_87	SARG|gi|895967513|ref|WP_049046752.1|	38.1	252	284	648	2.77e-42	152
k141_28508_87	SARG|gi|779903733|ref|WP_045374054.1|	38.1	252	284	648	2.77e-42	152
k141_28508_87	SARG|gi|895981299|ref|WP_049056431.1|	38.7	243	284	648	1.37e-41	150
k141_28508_87	SARG|gi|823281237|ref|WP_047037467.1|	38.7	243	284	648	1.37e-41	150
k141_28508_87	SARG|gi|505180394|ref|WP_015367496.1|	39.7	234	284	648	2.60e-41	149
k141_28508_87	SARG|gi|936194420|ref|WP_054528571.1|	37.9	240	284	648	4.92e-41	149
k141_28508_87	SARG|gi|823326845|ref|WP_047080664.1|	39.3	234	284	648	4.92e-41	149
k141_28508_87	SARG|gi|696368937|ref|WP_032943949.1|	38.8	240	284	648	4.92e-41	149
k141_28508_87	SARG|gi|851913025|ref|WP_048215946.1|	38.8	240	284	648	4.92e-41	149
k141_28508_87	SARG|gi|489930965|ref|WP_003834285.1|	38.8	240	284	648	4.92e-41	149
k141_28508_94	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	30.1	216	237	293	4.80e-28	107
k141_28508_94	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	28.6	231	237	307	6.41e-22	90.9
k141_28508_94	SARG|P42332	26.2	229	237	306	6.18e-21	88.2
k141_28508_94	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	26.2	229	237	306	6.18e-21	88.2
k141_28508_94	SARG|gi|510143239|gb|AGN36970.1|	26.2	229	237	313	6.76e-21	88.2
k141_28508_94	SARG|AAD21213	26.2	229	237	306	8.55e-21	87.8
k141_28508_94	SARG|ABB80128	25.8	229	237	306	3.12e-20	86.3
k141_28508_94	SARG|gb|AAC74000.1|ARO:3003950|msbA	24.2	215	237	582	2.83e-07	49.7
k141_28508_94	SARG|gi|817122037|ref|WP_046494699.1|	21.0	233	237	613	2.23e-06	47.0
k141_28508_94	SARG|gi|799286378|ref|WP_045936958.1|	23.8	244	237	620	2.24e-06	47.0
k141_28508_98	SARG|AF139725.gene.p01	41.7	48	193	214	9.83e-06	43.5
k141_28508_98	SARG|AAF24171	41.7	48	193	214	9.83e-06	43.5
k141_28508_98	NCBI|WP_063856931.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	41.7	48	193	214	9.83e-06	43.5
k141_28508_98	NCBI|WP_063856932.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	41.7	48	193	214	9.83e-06	43.5
k141_28508_98	NCBI|WP_063856933.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	41.7	48	193	214	9.83e-06	43.5
k141_28508_98	NCBI|WP_063856934.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	41.7	48	193	214	9.83e-06	43.5
k141_28508_98	SARG|AAG21695	41.7	48	193	214	9.83e-06	43.5
k141_28508_98	SARG|AAK91782	41.7	48	193	214	9.83e-06	43.5
k141_28508_102	SARG|gi|500194536|ref|WP_011867743.1|	28.4	225	502	306	2.56e-20	90.5
k141_28508_102	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	25.7	222	502	307	3.21e-18	84.3
k141_28508_102	SARG|gb|AAC75271.1|ARO:3003952|yojI	27.8	216	502	547	7.21e-13	69.7
k141_28508_102	SARG|gb|AAK76137.1|ARO:3000024|patA	22.9	223	502	564	2.84e-11	64.7
k141_28508_102	SARG|gi|542061059|gb|ERI11611.1|	27.8	223	502	316	1.25e-10	61.6
k141_28508_102	SARG|P42332	26.5	204	502	306	2.78e-10	60.5
k141_28508_102	SARG|ABB80128	26.5	204	502	306	2.78e-10	60.5
k141_28508_102	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	26.5	204	502	306	2.78e-10	60.5
k141_28508_102	SARG|gi|510143239|gb|AGN36970.1|	26.5	204	502	313	2.92e-10	60.5
k141_28508_102	SARG|gi|507055561|ref|WP_016126482.1|	26.5	226	502	309	5.08e-10	59.7
k141_28508_142	SARG|gi|754732608|ref|WP_042101370.1|	29.7	232	508	648	1.66e-22	100
k141_28508_142	SARG|gi|446110297|ref|WP_000188152.1|	29.7	232	508	648	1.66e-22	100
k141_28508_142	SARG|gi|910140813|ref|WP_050008485.1|	29.7	232	508	648	1.66e-22	100
k141_28508_142	SARG|gi|693170426|ref|WP_032302787.1|	30.2	232	508	648	9.28e-22	97.8
k141_28508_142	SARG|gi|654658955|ref|WP_028119847.1|	31.1	228	508	648	2.19e-21	96.7
k141_28508_142	SARG|gi|550712535|ref|WP_022645444.1|	29.6	233	508	648	2.91e-21	96.3
k141_28508_142	SARG|gi|693106883|ref|WP_032260279.1|	29.7	232	508	648	3.87e-21	95.9
k141_28508_142	SARG|gi|1036100176|ref|WP_064669414.1|	29.3	232	508	648	3.87e-21	95.9
k141_28508_142	SARG|gi|446110264|ref|WP_000188119.1|	29.3	232	508	648	3.87e-21	95.9
k141_28508_142	SARG|gi|446110265|ref|WP_000188120.1|	31.1	228	508	648	3.87e-21	95.9
k141_28624_6	SARG|gi|446048013|ref|WP_000125868.1|	29.4	231	504	648	9.07e-23	100
k141_28624_6	SARG|gi|445996710|ref|WP_000074565.1|	27.0	252	504	309	7.42e-19	86.3
k141_28624_6	SARG|gi|446026113|ref|WP_000103968.1|	23.9	243	504	306	9.61e-19	85.9
k141_28624_6	SARG|gi|445996729|ref|WP_000074584.1|	26.0	250	504	309	1.35e-18	85.5
k141_28624_6	SARG|gi|445996719|ref|WP_000074574.1|	27.8	216	504	309	1.82e-18	85.1
k141_28624_6	SARG|gi|895736250|emb|COF64653.1|	26.0	250	504	309	2.46e-18	84.7
k141_28624_6	SARG|gi|445996714|ref|WP_000074569.1|	26.0	250	504	309	2.46e-18	84.7
k141_28624_6	SARG|gi|895808656|emb|COR83787.1|	26.0	250	504	309	2.46e-18	84.7
k141_28624_6	SARG|gi|507023808|ref|WP_016095885.1|	25.2	250	504	309	3.32e-18	84.3
k141_28624_6	SARG|gi|488068784|ref|WP_002140181.1|	25.2	250	504	309	3.32e-18	84.3
k141_28624_32	SARG|DQ212986.1.gene3.p01	52.2	67	76	75	2.73e-20	75.5
k141_23868_4	megares|MEG_3786|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	31.1	164	736	585	4.67e-12	68.2
k141_23868_4	NCBI|WP_000952923.1|1|1|mecR1|mecR1|regulation|2|METHICILLIN|beta-lactam|beta-lactam_sensor/signal_transducer_MecR1|AMR|beta-lactam	31.1	164	736	585	4.67e-12	68.2
k141_23868_7	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	70.0	307	308	307	2.15e-149	420
k141_23868_7	SARG|gi|445996710|ref|WP_000074565.1|	52.6	302	308	309	7.16e-100	295
k141_23868_7	SARG|gi|445996708|ref|WP_000074563.1|	52.6	302	308	309	1.01e-99	294
k141_23868_7	SARG|gi|445996719|ref|WP_000074574.1|	52.3	302	308	309	1.44e-99	294
k141_23868_7	SARG|gi|895736250|emb|COF64653.1|	52.3	302	308	309	4.09e-99	293
k141_23868_7	SARG|gi|542061059|gb|ERI11611.1|	52.0	302	308	316	5.14e-99	293
k141_23868_7	SARG|gi|446110087|ref|WP_000187942.1|	52.3	302	308	309	5.79e-99	292
k141_23868_7	SARG|gi|447057510|ref|WP_001134766.1|	52.0	302	308	309	8.21e-99	292
k141_23868_7	SARG|gi|895808656|emb|COR83787.1|	52.3	302	308	309	8.21e-99	292
k141_23868_7	SARG|gi|445996729|ref|WP_000074584.1|	52.3	302	308	309	1.16e-98	291
k141_23868_8	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	33.0	215	305	364	4.29e-29	113
k141_23868_8	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	33.0	215	305	364	4.29e-29	113
k141_23868_8	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.6	287	305	354	9.57e-28	109
k141_23868_8	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.3	231	305	354	1.83e-27	108
k141_23868_8	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	30.1	246	305	364	2.12e-27	108
k141_23868_8	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	30.1	246	305	364	2.12e-27	108
k141_23868_8	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.9	261	305	367	4.22e-27	107
k141_23868_8	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.7	246	305	352	4.72e-27	107
k141_23868_8	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.9	260	305	381	5.08e-27	107
k141_23868_8	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.9	260	305	381	5.08e-27	107
k141_23868_9	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	38.1	231	231	233	1.08e-55	176
k141_23868_9	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.7	229	231	231	2.04e-55	176
k141_23868_9	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.7	229	231	231	1.16e-54	174
k141_23868_9	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.7	229	231	231	1.16e-54	174
k141_23868_9	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	36.8	228	231	231	1.16e-54	174
k141_23868_9	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.4	229	231	229	1.54e-54	173
k141_23868_9	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.2	229	231	231	1.31e-53	171
k141_23868_9	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	36.1	230	231	230	1.80e-53	171
k141_23868_9	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.1	225	231	231	7.42e-53	169
k141_23868_9	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	36.1	233	231	235	5.34e-51	164
k141_23868_23	SARG|gi|851935911|ref|WP_048224705.1|	32.4	250	327	660	1.10e-42	155
k141_23868_23	SARG|gi|693024424|ref|WP_032201428.1|	32.9	258	327	660	1.10e-42	155
k141_23868_23	SARG|gi|446571412|ref|WP_000648758.1|	32.3	257	327	660	2.85e-42	154
k141_23868_23	SARG|gi|693029841|ref|WP_032205568.1|	32.6	258	327	660	3.92e-42	153
k141_23868_23	SARG|gi|685229372|ref|WP_031601992.1|	32.7	257	327	660	3.92e-42	153
k141_23868_23	SARG|gi|446571423|ref|WP_000648769.1|	29.5	329	327	660	3.92e-42	153
k141_23868_23	SARG|gi|446783015|ref|WP_000860271.1|	32.6	258	327	660	5.39e-42	153
k141_23868_23	SARG|gi|487613526|ref|WP_001735490.1|	32.6	258	327	660	5.39e-42	153
k141_23868_23	SARG|gi|487375894|ref|WP_001649055.1|	32.6	258	327	660	5.39e-42	153
k141_23868_23	SARG|gi|851899656|ref|WP_048211088.1|	31.8	283	327	660	5.39e-42	153
k141_23868_26	NCBI|WP_002349981.1|1|1|cfr(B)|cfr(B)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/LINEZOLID/RETAPAMULIN/STREPTOGRAMIN_B/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(B)|AMR|multidrug	36.2	309	343	349	5.27e-59	192
k141_23868_26	SARG|gb|CDF47262.1|ARO:3004649|cfr(B)	35.9	309	343	349	2.07e-58	191
k141_23868_26	SARG|gb|AIX48090.1|ARO:3004599|clcD	35.6	309	343	349	5.77e-58	190
k141_23868_28	CARD|gb|WKR28567.1|ARO:3007678|IreK	35.3	612	715	718	2.83e-89	293
k141_59676_25	CARD|gb|AAC75429.1|ARO:3000833|evgS	28.1	374	869	1197	3.94e-29	124
k141_59676_34	SARG|gi|542061059|gb|ERI11611.1|	29.6	213	494	316	4.80e-13	68.9
k141_59676_34	SARG|gb|AAK76137.1|ARO:3000024|patA	23.1	290	494	564	5.40e-13	70.1
k141_59676_34	SARG|ZP_04081918	29.9	211	494	306	1.47e-11	64.3
k141_59676_34	SARG|gi|500194536|ref|WP_011867743.1|	27.9	208	494	306	2.64e-11	63.5
k141_59676_34	SARG|gi|445996710|ref|WP_000074565.1|	27.9	215	494	309	4.84e-11	62.8
k141_59676_34	SARG|gi|447195835|ref|WP_001273091.1|	28.9	211	494	306	1.13e-10	61.6
k141_59676_34	SARG|gi|447195836|ref|WP_001273092.1|	28.9	211	494	306	1.13e-10	61.6
k141_59676_34	SARG|gi|500448961|gb|EOP61695.1|	29.5	210	494	306	1.52e-10	61.2
k141_59676_34	SARG|gi|500465078|gb|EOP76697.1|	28.1	217	494	306	1.52e-10	61.2
k141_59676_34	SARG|gi|895736250|emb|COF64653.1|	27.4	215	494	309	1.55e-10	61.2
k141_59676_64	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	33.6	238	890	357	3.59e-29	119
k141_59676_64	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	33.6	238	890	357	3.59e-29	119
k141_59676_64	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	30.2	281	890	370	7.92e-26	109
k141_59676_64	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	29.2	281	890	365	1.55e-23	102
k141_59676_64	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	29.3	242	890	392	4.26e-22	98.6
k141_59676_64	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.7	253	890	354	2.05e-21	95.9
k141_59676_64	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.8	227	890	352	1.18e-20	93.6
k141_59676_64	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.8	230	890	376	1.60e-20	93.6
k141_59676_64	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	27.8	230	890	376	1.60e-20	93.6
k141_59676_64	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.5	230	890	354	3.94e-20	92.0
k141_59676_65	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	47.6	229	234	232	2.09e-74	224
k141_59676_65	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	47.6	229	234	232	2.09e-74	224
k141_59676_65	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	46.0	226	234	231	1.42e-69	212
k141_59676_65	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	46.0	226	234	231	1.42e-69	212
k141_59676_65	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.1	226	234	231	4.05e-69	211
k141_59676_65	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	44.6	231	234	239	5.96e-68	208
k141_59676_65	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	44.7	226	234	231	6.57e-68	207
k141_59676_65	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	44.7	226	234	231	1.32e-67	207
k141_59676_65	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	43.0	228	234	229	3.52e-67	206
k141_59676_65	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	44.1	229	234	233	3.23e-66	203
k141_100582_17	SARG|YP_001186705	26.2	1016	1028	1017	1.46e-87	302
k141_100582_17	CARD|gb|AAC75137.1|ARO:3000794|mdtC	25.9	1008	1028	1025	1.97e-83	291
k141_100582_17	SARG|YP_792720	25.9	1014	1028	1018	1.23e-80	283
k141_100582_17	SARG|AAG07763	25.9	1014	1028	1018	1.23e-80	283
k141_100582_17	SARG|YP_350221	25.0	1016	1028	1009	7.07e-80	280
k141_100582_17	SARG|CAY51926	25.0	1018	1028	1008	1.30e-79	280
k141_100582_17	SARG|YP_001350280	25.9	1014	1028	1018	2.00e-79	279
k141_100582_17	SARG|YP_001670703	26.2	1024	1028	1014	1.22e-78	277
k141_100582_17	SARG|YP_001266290	25.9	1019	1028	1014	3.07e-78	276
k141_100582_17	SARG|YP_606823	25.0	1014	1028	1011	2.56e-77	273
k141_100909_7	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.7	529	547	655	3.03e-66	226
k141_100909_7	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.7	529	547	655	4.21e-66	225
k141_100909_7	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	529	547	655	4.21e-66	225
k141_100909_7	SARG|gb|AKA86814|ARO:3003746|optrA	29.5	529	547	655	4.21e-66	225
k141_100909_7	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	529	547	655	1.13e-65	224
k141_100909_7	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	529	547	655	1.13e-65	224
k141_100909_7	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.7	529	547	655	1.13e-65	224
k141_100909_7	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	529	547	655	1.13e-65	224
k141_100909_7	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	529	547	655	1.13e-65	224
k141_100909_7	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	529	547	655	1.57e-65	224
k141_100909_17	SARG|AUI09862.1	46.3	270	272	287	1.50e-84	253
k141_100909_17	SARG|AJ459418.gene.p01	33.3	261	272	263	1.62e-43	147
k141_100909_17	SARG|gi|970263436|ref|WP_058647620.1|	33.0	261	272	263	3.53e-42	144
k141_100909_17	SARG|gi|749031651|ref|WP_040079219.1|	31.1	267	272	279	1.45e-37	132
k141_100909_17	SARG|gi|1028098535|ref|WP_063855037.1|	31.5	267	272	279	5.63e-37	131
k141_100909_17	SARG|gi|836565187|ref|WP_047723567.1|	31.1	267	272	279	1.11e-36	130
k141_100909_17	SARG|ABQ96629	30.7	267	272	279	4.30e-36	129
k141_100909_17	megares|MEG_6614|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI_1	30.7	267	272	278	5.89e-36	128
k141_100909_17	SARG|gi|638931161|ref|WP_024439378.1|	30.7	267	272	278	5.89e-36	128
k141_100909_17	SARG|gi|691356724|ref|WP_032072921.1|	30.7	267	272	279	6.03e-36	128
k141_52481_3	CARD|gb|AAC75429.1|ARO:3000833|evgS	26.6	455	1057	1197	3.07e-30	128
k141_52481_3	CARD|gb|ADM92606.1|ARO:3000549|adeS	26.4	231	1057	361	1.93e-17	84.3
k141_52481_3	CARD|gb|AAD51347.1|ARO:3003067|smeS	28.4	292	1057	467	1.28e-14	76.6
k141_52481_3	CARD|gb|AEX49906.1|ARO:3003583|basS	27.8	270	1057	477	1.33e-14	76.6
k141_52481_3	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	23.8	269	1057	359	4.82e-14	73.9
k141_52481_3	SARG|ZP_02848503	32.8	122	1057	221	6.46e-11	62.4
k141_52481_3	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.0	122	1057	219	2.81e-10	60.5
k141_52481_3	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.0	122	1057	219	2.81e-10	60.5
k141_52481_3	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.0	122	1057	220	2.85e-10	60.5
k141_52481_3	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.1	122	1057	220	9.46e-10	58.9
k141_52481_10	SARG|YP_002861121	41.1	56	209	212	3.35e-11	59.3
k141_52481_10	SARG|YP_001779894	41.1	56	209	212	6.35e-11	58.5
k141_52481_10	SARG|YP_001389621	39.3	56	209	212	1.65e-10	57.4
k141_52481_10	SARG|YP_001785579	39.3	56	209	212	3.11e-10	56.6
k141_52481_10	NCBI|WP_031281281.1|1|1|catB|catB|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B_phenicol_O-acetyltransferase|AMR|phenicol	43.1	58	209	210	4.17e-10	56.2
k141_52481_10	SARG|M58472.1.gene1.p01	39.7	58	209	209	5.66e-10	55.8
k141_52481_10	SARG|1XAT	37.8	74	209	212	2.07e-09	54.3
k141_52481_10	SARG|CAW29378	37.8	74	209	206	2.66e-09	53.9
k141_52481_10	SARG|AF036933.1.gene1.p01	37.8	74	209	212	2.83e-09	53.9
k141_52481_10	SARG|YP_002085096	37.8	74	209	212	2.83e-09	53.9
k141_52481_13	SARG|gb|AAK76137.1|ARO:3000024|patA	27.7	220	497	564	8.52e-11	63.2
k141_52481_13	SARG|AF170880.4.gene1.p01	24.3	214	497	615	1.19e-10	62.8
k141_52481_13	SARG|gi|948137056|ref|WP_056795395.1|	24.2	223	497	602	4.75e-10	60.8
k141_52481_13	SARG|gi|558888514|ref|WP_023543283.1|	23.4	214	497	615	6.36e-10	60.5
k141_52481_13	SARG|gi|917155568|ref|WP_051762280.1|	25.3	249	497	620	1.12e-09	59.7
k141_52481_13	SARG|gi|917166849|ref|WP_051773561.1|	25.3	249	497	620	1.12e-09	59.7
k141_52481_13	SARG|gi|953808775|ref|WP_058042812.1|	25.2	222	497	608	1.93e-09	58.9
k141_52481_13	SARG|gi|505420018|ref|WP_015607120.1|	24.3	243	497	603	2.53e-09	58.5
k141_52481_13	SARG|gi|860594225|ref|WP_048475168.1|	25.8	209	497	620	2.57e-09	58.5
k141_52481_13	SARG|gi|695842130|ref|WP_032755430.1|	23.9	243	497	603	3.35e-09	58.2
